Carcinoembryonic Antigen: A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.Antigens, Neoplasm: Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.Antigens: Substances that are recognized by the immune system and induce an immune reaction.Colonic Neoplasms: Tumors or cancer of the COLON.Antigens, Tumor-Associated, Carbohydrate: Carbohydrate antigens expressed by malignant tissue. They are useful as tumor markers and are measured in the serum by means of a radioimmunoassay employing monoclonal antibodies.CA-19-9 Antigen: Sialylated Lewis blood group carbohydrate antigen found in many adenocarcinomas of the digestive tract, especially pancreatic tumors.Cell Adhesion Molecules: Surface ligands, usually glycoproteins, that mediate cell-to-cell adhesion. Their functions include the assembly and interconnection of various vertebrate systems, as well as maintenance of tissue integration, wound healing, morphogenic movements, cellular migrations, and metastasis.Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.Antigens, Bacterial: Substances elaborated by bacteria that have antigenic activity.Antigens, Surface: Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.Keratin-19: A type I keratin found associated with KERATIN-7 in ductal epithelia and gastrointestinal epithelia.Adenocarcinoma: A malignant epithelial tumor with a glandular organization.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Tumor Markers, Biological: Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.Antigens, CD: Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.Rectal Neoplasms: Tumors or cancer of the RECTUM.Mucin-1: Carbohydrate antigen elevated in patients with tumors of the breast, ovary, lung, and prostate as well as other disorders. The mucin is expressed normally by most glandular epithelia but shows particularly increased expression in the breast at lactation and in malignancy. It is thus an established serum marker for breast cancer.Tissue Polypeptide Antigen: Serological tumor marker composed of a molecular complex of cytokeratins 8, 18, and 19. It is used in the diagnosis and staging of bronchogenic carcinoma.Cystadenocarcinoma: A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)Antigens, Viral: Substances elaborated by viruses that have antigenic activity.Immunoenzyme Techniques: Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.Radioimmunoassay: Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation.Epitopes: Sites on an antigen that interact with specific antibodies.Perchlorates: Compounds that contain the Cl(=O)(=O)(=O)O- structure. Included under this heading is perchloric acid and the salts and ester forms of perchlorate.Glycoproteins: Conjugated protein-carbohydrate compounds including mucins, mucoid, and amyloid glycoproteins.alpha-Fetoproteins: The first alpha-globulins to appear in mammalian sera during FETAL DEVELOPMENT and the dominant serum proteins in early embryonic life.Keratins: A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.Gastrointestinal Neoplasms: Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.Antibodies, Neoplasm: Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.Liver Neoplasms: Tumors or cancer of the LIVER.Keratin-20: A type I keratin expressed predominately in gastrointestinal epithelia, MERKEL CELLS, and the TASTE BUDS of the oral mucosa.Cross Reactions: Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen.GPI-Linked Proteins: A subclass of lipid-linked proteins that contain a GLYCOSYLPHOSPHATIDYLINOSITOL LINKAGE which holds them to the CELL MEMBRANE.Cyst Fluid: Liquid material found in epithelial-lined closed cavities or sacs.Antibody Specificity: The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.Pregnancy-Specific beta 1-Glycoproteins: Glycoproteins with the electrophoretic mobility of BETA-GLOBULINS, secreted by the placental TROPHOBLASTS into the maternal bloodstream during PREGNANCY. They can be detected 18 days after OVULATION and reach 200 mg/ml at the end of pregnancy. They are associated with fetal well-being.Immunoglobulin Fragments: Partial immunoglobulin molecules resulting from selective cleavage by proteolytic enzymes or generated through PROTEIN ENGINEERING techniques.Cancer Vaccines: Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced.Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)Lung Neoplasms: Tumors or cancer of the LUNG.Cystadenoma: A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.Antigens, Differentiation: Antigens expressed primarily on the membranes of living cells during sequential stages of maturation and differentiation. As immunologic markers they have high organ and tissue specificity and are useful as probes in studies of normal cell development as well as neoplastic transformation.Iodine Radioisotopes: Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes.HLA-A2 Antigen: A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*02 allele family.CA-125 Antigen: Carbohydrate antigen most commonly seen in tumors of the ovary and occasionally seen in breast, kidney, and gastrointestinal tract tumors and normal tissue. CA 125 is clearly tumor-associated but not tumor-specific.Radioimmunodetection: Use of radiolabeled antibodies for diagnostic imaging of neoplasms. Antitumor antibodies are labeled with diverse radionuclides including iodine-131, iodine-123, indium-111, or technetium-99m and injected into the patient. Images are obtained by a scintillation camera.Molecular Sequence Data: Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.Tumor Cells, Cultured: Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.Antigens, Protozoan: Any part or derivative of any protozoan that elicits immunity; malaria (Plasmodium) and trypanosome antigens are presently the most frequently encountered.Neoplasm Staging: Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.Peritoneal Lavage: Washing out of the peritoneal cavity. The procedure is a diagnostic as well as a therapeutic technique following abdominal trauma or inflammation.Avipoxvirus: A genus of the family POXVIRIDAE, subfamily CHORDOPOXVIRINAE, comprising bird poxviruses. The type species is FOWLPOX VIRUS. Transmission is mechanical by ARTHROPODS.Antibodies, Anti-Idiotypic: Antibodies which react with the individual structural determinants (idiotopes) on the variable region of other antibodies.Neoplasm Transplantation: Experimental transplantation of neoplasms in laboratory animals for research purposes.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Antigens, Polyomavirus Transforming: Polyomavirus antigens which cause infection and cellular transformation. The large T antigen is necessary for the initiation of viral DNA synthesis, repression of transcription of the early region and is responsible in conjunction with the middle T antigen for the transformation of primary cells. Small T antigen is necessary for the completion of the productive infection cycle.Neoplasm Recurrence, Local: The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.Antigens, CD15: A trisaccharide antigen expressed on glycolipids and many cell-surface glycoproteins. In the blood the antigen is found on the surface of NEUTROPHILS; EOSINOPHILS; and MONOCYTES. In addition, CD15 antigen is a stage-specific embryonic antigen.Stomach Neoplasms: Tumors or cancer of the STOMACH.Radioimmunotherapy: Radiotherapy where cytotoxic radionuclides are linked to antibodies in order to deliver toxins directly to tumor targets. Therapy with targeted radiation rather than antibody-targeted toxins (IMMUNOTOXINS) has the advantage that adjacent tumor cells, which lack the appropriate antigenic determinants, can be destroyed by radiation cross-fire. Radioimmunotherapy is sometimes called targeted radiotherapy, but this latter term can also refer to radionuclides linked to non-immune molecules (see RADIOTHERAPY).HLA Antigens: Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases.Antibodies, Bispecific: Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors.Enzyme-Linked Immunosorbent Assay: An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.Mice, Inbred BALB CReceptors, Antigen: Molecules on the surface of B- and T-lymphocytes that recognize and combine with specific antigens.Antigens, CD58: Glycoproteins with a wide distribution on hematopoietic and non-hematopoietic cells and strongly expressed on macrophages. CD58 mediates cell adhesion by binding to CD2; (ANTIGENS, CD2); and this enhances antigen-specific T-cell activation.Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.Mice, Nude: Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.Cell Line: Established cell cultures that have the potential to propagate indefinitely.Sigmoid Neoplasms: Tumors or cancer of the SIGMOID COLON.Phosphopyruvate Hydratase: A hydro-lyase that catalyzes the dehydration of 2-phosphoglycerate to form PHOSPHOENOLPYRUVATE. Several different isoforms of this enzyme exist, each with its own tissue specificity.Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.Cecal Neoplasms: Tumors or cancer of the CECUM.Transplantation, Heterologous: Transplantation between animals of different species.Immunoglobulin G: The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.Antigens, Fungal: Substances of fungal origin that have antigenic activity.Amino Acid Sequence: The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.Immunodiffusion: Technique involving the diffusion of antigen or antibody through a semisolid medium, usually agar or agarose gel, with the result being a precipitin reaction.Carcinoma, Medullary: A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)Membrane Glycoproteins: Glycoproteins found on the membrane or surface of cells.Immunoradiometric Assay: Form of radioimmunoassay in which excess specific labeled antibody is added directly to the test antigen being measured.Adenocarcinoma, Mucinous: An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)Colon: The segment of LARGE INTESTINE between the CECUM and the RECTUM. It includes the ASCENDING COLON; the TRANSVERSE COLON; the DESCENDING COLON; and the SIGMOID COLON.Antigens, Helminth: Any part or derivative of a helminth that elicits an immune reaction. The most commonly seen helminth antigens are those of the schistosomes.Pleural Effusion, Malignant: Presence of fluid in the PLEURAL CAVITY as a complication of malignant disease. Malignant pleural effusions often contain actual malignant cells.Pancreatic Cyst: A true cyst of the PANCREAS, distinguished from the much more common PANCREATIC PSEUDOCYST by possessing a lining of mucous EPITHELIUM. Pancreatic cysts are categorized as congenital, retention, neoplastic, parasitic, enterogenous, or dermoid. Congenital cysts occur more frequently as solitary cysts but may be multiple. Retention cysts are gross enlargements of PANCREATIC DUCTS secondary to ductal obstruction. (From Bockus Gastroenterology, 4th ed, p4145)Carcinoma, Bronchogenic: Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.H-2 Antigens: The major group of transplantation antigens in the mouse.Heterogeneous-Nuclear Ribonucleoprotein Group M: A group of closely-related 72-74-kDa heterogeneous-nuclear ribonucleoproteins that are involved in RNA SPLICING events.Carbohydrates: The largest class of organic compounds, including STARCH; GLYCOGEN; CELLULOSE; POLYSACCHARIDES; and simple MONOSACCHARIDES. Carbohydrates are composed of carbon, hydrogen, and oxygen in a ratio of Cn(H2O)n.Base Sequence: The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.Immunologic Techniques: Techniques used to demonstrate or measure an immune response, and to identify or measure antigens using antibodies.T-Lymphocytes: Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.Antigen-Antibody Reactions: The processes triggered by interactions of ANTIBODIES with their ANTIGENS.Breast Neoplasms: Tumors or cancer of the human BREAST.Fowlpox virus: The type species of the genus AVIPOXVIRUS. It is the etiologic agent of FOWLPOX.Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).Digestive System Diseases: Diseases in any part of the GASTROINTESTINAL TRACT or the accessory organs (LIVER; BILIARY TRACT; PANCREAS).Calcitonin: A peptide hormone that lowers calcium concentration in the blood. In humans, it is released by thyroid cells and acts to decrease the formation and absorptive activity of osteoclasts. Its role in regulating plasma calcium is much greater in children and in certain diseases than in normal adults.Antigens, CD3: Complex of at least five membrane-bound polypeptides in mature T-lymphocytes that are non-covalently associated with one another and with the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL). The CD3 complex includes the gamma, delta, epsilon, zeta, and eta chains (subunits). When antigen binds to the T-cell receptor, the CD3 complex transduces the activating signals to the cytoplasm of the T-cell. The CD3 gamma and delta chains (subunits) are separate from and not related to the gamma/delta chains of the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA).Secretory Component: The extracellular moiety of the POLYMERIC IMMUNOGLOBULIN RECEPTOR found alone or complexed with IGA or IGM, in a variety of external secretions (tears, bile, colostrum.) Secretory component is derived by proteolytic cleavage of the receptor during transcytosis. When immunoglobulins IgA and IgM are bound to the receptor, during their transcytosis secretory component becomes covalently attached to them generating SECRETORY IMMUNOGLOBULIN A or secretory IMMUNOGLOBULIN M.HLA-DR Antigens: A subclass of HLA-D antigens that consist of alpha and beta chains. The inheritance of HLA-DR antigens differs from that of the HLA-DQ ANTIGENS and HLA-DP ANTIGENS.T-Lymphocytes, Cytotoxic: Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.Antigens, Viral, Tumor: Those proteins recognized by antibodies from serum of animals bearing tumors induced by viruses; these proteins are presumably coded for by the nucleic acids of the same viruses that caused the neoplastic transformation.Keratin-7: A type II keratin found associated with KERATIN-19 in ductal epithelia and gastrointestinal epithelia.False Positive Reactions: Positive test results in subjects who do not possess the attribute for which the test is conducted. The labeling of healthy persons as diseased when screening in the detection of disease. (Last, A Dictionary of Epidemiology, 2d ed)Immunoassay: A technique using antibodies for identifying or quantifying a substance. Usually the substance being studied serves as antigen both in antibody production and in measurement of antibody by the test substance.Immune Sera: Serum that contains antibodies. It is obtained from an animal that has been immunized either by ANTIGEN injection or infection with microorganisms containing the antigen.RNA, Messenger: RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.Antibodies: Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).Predictive Value of Tests: In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.Neoplastic Cells, Circulating: Exfoliate neoplastic cells circulating in the blood and associated with metastasizing tumors.Fluorescent Antibody Technique: Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy.Immunoelectrophoresis: A technique that combines protein electrophoresis and double immunodiffusion. In this procedure proteins are first separated by gel electrophoresis (usually agarose), then made visible by immunodiffusion of specific antibodies. A distinct elliptical precipitin arc results for each protein detectable by the antisera.Lymphocyte Activation: Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.Lymphatic Metastasis: Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Antigen-Antibody Complex: The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes IMMUNE COMPLEX DISEASES.Peritoneal Neoplasms: Tumors or cancer of the PERITONEUM.Immunoglobulin Fab Fragments: Univalent antigen-binding fragments composed of one entire IMMUNOGLOBULIN LIGHT CHAIN and the amino terminal end of one of the IMMUNOGLOBULIN HEAVY CHAINS from the hinge region, linked to each other by disulfide bonds. Fab contains the IMMUNOGLOBULIN VARIABLE REGIONS, which are part of the antigen-binding site, and the first IMMUNOGLOBULIN CONSTANT REGIONS. This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.Receptors, Antigen, T-Cell: Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (ANTIGENS, CD3). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains.Antigens, CD80: A costimulatory ligand expressed by ANTIGEN-PRESENTING CELLS that binds to CTLA-4 ANTIGEN with high specificity and to CD28 ANTIGEN with low specificity. The interaction of CD80 with CD28 ANTIGEN provides a costimulatory signal to T-LYMPHOCYTES, while its interaction with CTLA-4 ANTIGEN may play a role in inducing PERIPHERAL TOLERANCE.Recombinant Fusion Proteins: Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.Antibody Formation: The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.Murine hepatitis virus: A species of the CORONAVIRUS genus causing hepatitis in mice. Four strains have been identified as MHV 1, MHV 2, MHV 3, and MHV 4 (also known as MHV-JHM, which is neurotropic and causes disseminated encephalomyelitis with demyelination as well as focal liver necrosis).Molecular Weight: The sum of the weight of all the atoms in a molecule.Flow Cytometry: Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.Histocompatibility Antigens: A group of antigens that includes both the major and minor histocompatibility antigens. The former are genetically determined by the major histocompatibility complex. They determine tissue type for transplantation and cause allograft rejections. The latter are systems of allelic alloantigens that can cause weak transplant rejection.Goats: Any of numerous agile, hollow-horned RUMINANTS of the genus Capra, in the family Bovidae, closely related to the SHEEP.Tissue Distribution: Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios.Reagent Kits, Diagnostic: Commercially prepared reagent sets, with accessory devices, containing all of the major components and literature necessary to perform one or more designated diagnostic tests or procedures. They may be for laboratory or personal use.Proliferating Cell Nuclear Antigen: Nuclear antigen with a role in DNA synthesis, DNA repair, and cell cycle progression. PCNA is required for the coordinated synthesis of both leading and lagging strands at the replication fork during DNA replication. PCNA expression correlates with the proliferation activity of several malignant and non-malignant cell types.Nipples: The conic organs which usually give outlet to milk from the mammary glands.ROC Curve: A graphic means for assessing the ability of a screening test to discriminate between healthy and diseased persons; may also be used in other studies, e.g., distinguishing stimuli responses as to a faint stimuli or nonstimuli.

Classification of human colorectal adenocarcinoma cell lines. (1/2094)

Eleven human colorectal adenocarcinoma cell lines established in this laboratory were classified into three groups based on morphological features (light and electron microscopy), modal chromosome number, and ability to synthesize carcinoembryonic antigen (CEA). Group 1 cell lines contained both dedifferentiated and differentiating cells growing in tight clusters or islands of epithelium-like cells; their modal chromosome number was about 47, and they synthesized small to moderate amounts of CEA. Group 2 cell lines were more dedifferentiated, were hyperdiploid, and synthesized small amounts of CEA. Group 3 cell lines were morphologically similar to those of Group 1 by light microscopy. They differed ultrastructurally by containing microvesicular bodies; the modal chromosome number varied from hyperdiploid to hypertriploid or they had bimodal populations of hypodiploid and hypertriploid cells, and they synthesized relatively large amounts of CEA. No correlation could be found between Broder's grade or Duke's classification of the original tumor and modal chromosome number or ability to synthesize CEA. These findings support Nowell's hypothesis that the stem line is different for each solid tumor, which makes it difficult to relate chromosomal changes to the initiation of the neoplastic state.  (+info)

Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen. (2/2094)

Marimastat is a specific inhibitor of matrix metalloproteinases that has been shown to be effective in cancer models. A pilot, escalating-dose study of oral marimastat was performed in patients with recurrent colorectal cancer, in whom evaluation of serological response was made by measurement of carcinoembryonic antigen (CEA) levels. The study assessed the safety and tolerability of 4 weeks administration of marimastat, and determined a dose range producing detectable serological effects. Patients were recruited with a serum CEA level greater than 5 ng ml(-1), and rising by more than 25% over a 4-week screening period. Patients were treated for 28 days and entered into a continuation protocol if a serological response or clinical benefit was observed. Pharmacokinetic and safety data determined that groups of patients were recruited sequentially at 25 mg and 50 mg twice daily, and, thereafter, 10 mg twice daily, 10 mg once daily, 5 mg once daily and 20 mg once daily. A biological effect (BE) was defined as a CEA value on day 28 no greater than on day 0; a partial biological effect (PBE) was defined as a rise in CEA over the 28-day treatment period of less than 25%. Of 70 patients recruited, 63 completed the 28-day treatment period, and 55 were eligible for cancer antigen analysis. Examination of the dose-effect relationships provides evidence for a causal relationship between marimastat and biological effects: the proportion of patients with BE or PBE was higher with twice daily dosing (16 out of 25, 64%) than with once daily dosing (11 out of 30, 37%) (P = 0.043, chi2 test). Furthermore, the median rates of rise of CEA fell markedly during treatment compared with the screening period for patients receiving twice daily marimastat (P<0.0001), but not for patients receiving marimastat once daily (P = 0.25). Musculoskeletal adverse events emerged as the principal drug-related toxicity of marimastat, occurring in a dose- and time-dependent fashion. It was concluded that marimastat was associated with dose-dependent biological effects in cancer patients. The occurrence of musculoskeletal side-effects define 25 mg twice daily as the upper limit of the dose range for continuous use in further studies. Therefore, a dose range of 20 mg once daily to 25 mg twice daily seems appropriate for further studies, which should aim to demonstrate the efficacy of the drug in terms of conventional clinical end points and describe the long-term tolerability of this novel agent.  (+info)

Detection of occult lymph node metastases in esophageal cancer by minimally invasive staging combined with molecular diagnostic techniques. (3/2094)

BACKGROUND AND OBJECTIVES: Lymph node metastases are the most important prognostic factor in patients with esophageal cancer. Histologic examination misses micrometastases in up to 20% of lymph nodes evaluated. In addition, non-invasive imaging modalities are not sensitive enough to detect small lymph nodes metastases. The objective of this study was to investigate the use of reverse transcriptase-polymerase chain reaction (RT-PCR) of messenger RNA (mRNA) for carcinoembryonic antigen (CEA) to increase the detection of micrometastases in lymph nodes from patients with esophageal cancer. METHODS: RT-PCR of CEA mRNA was performed in lymph nodes from patients with malignant and benign esophageal disease. Each specimen was examined histopathologically and by RT-PCR and the results were compared. RESULTS: Metastases were present in 29 of 60 (48%) lymph nodes sample by minimally invasive staging from 13 patients with esophageal cancer when examined histopathologically. RT-PCR identified nodal metastases in 46 of these 60 (77%) samples. RT-PCR detected CEA mRNA in all 29 histologically positive samples and in 17 histologically negative lymph nodes. All lymph nodes from patients with benign disease (n = 15) were negative both histopathologically and by RT-PCR. The stage of two patients was reclassified based on the RT-PCR results, which identified lymph node spread undetected histopathologically. Both of these patients developed recurrent disease after resection of the primary tumor. CONCLUSIONS: RT-PCR is more sensitive than histologic examination in the detection of lymph node metastases in esophageal cancer and can lead to diagnosis of a more advanced stage in some patients. The combination of minimally invasive surgical techniques in combination with new molecular diagnostic techniques may improve our ability to stage cancer patients.  (+info)

The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy. (4/2094)

Bone scintigraphy (BS) is commonly performed in the staging and postoperative monitoring of breast cancer. Nevertheless, due to low specificity it often demonstrates hot spots with equivocal interpretation, which may be misleading in the management of these patients. The aim of this study was to assess the value of a serum tumour marker panel in selecting among the patients with equivocal BS those with bone metastases. Between January 1986 and December 1995, 297 breast cancer patients were followed-up after mastectomy with serial determinations of a CEA-TPA-CA15.3 tumour marker panel, BS and liver echography. The tumour marker panel was used to select patients with equivocal BS for examination of suspicious bone areas by further imaging techniques. Up to December 1995, 158 (53%) patients showed an equivocal BS and 47 patients developed bone metastases. In the 158 patients with equivocal BS, prolonged clinical and imaging follow-up over 45 months (mean; range 12-120) was used to ascertain the presence or absence of bone metastases. In these 158 patients the negative predictive value and positive predictive value of the tumour marker panel to predict bone metastases was 97% and 75% respectively. This study shows that in breast cancer patients the CEA-TPA-CA15.3 tumour marker panel has a high value in selecting those patients with bone metastases, or at high risk of developing clinically-evident bone metastases, among the large number of subjects with equivocal BS.  (+info)

Serum YKL-40 and colorectal cancer. (5/2094)

YKL-40 is a mammalian member of the chitinase protein family. Although the function of YKL-40 is unknown, the pattern of its expression suggests a function in remodelling or degradation of extracellular matrix. High serum YKL-40 has been found in patients with recurrent breast cancer and has been related to short survival. In the present study we analysed YKL-40 in preoperative sera from patients with colorectal cancer and evaluated its relation to survival. Serum YKL-40 was determined by RIA in 603 patients. Survival after operation was registered, and median follow-up time was 61 months. Three hundred and forty patients died. Sixteen per cent of the patients with Dukes' A, 26% with Dukes' B, 19% with Dukes' C and 39% with Dukes' D had high serum YKL-40 levels (adjusted for age). Analysis of serum YKL-40 as a continuous variable showed an association between increased serum YKL-40 and short survival (P < 0.0001). Patients with high preoperative serum YKL-40 concentration had significantly shorter survival than patients with normal YKL-40 (HR = 1.7; 95% CI: 1.3-2.1, P < 0.0001). Multivariate Cox analysis including serum YKL-40, serum CEA, Dukes' stage, age and gender showed that high YKL-40 was an independent prognostic variable for short survival (HR = 1.4; 95% CI: 1.1-1.8, P = 0.007). These results suggest that YKL-40 may play an important role in tumour invasion.  (+info)

Intratumoral distribution of radiolabeled antibody and radioimmunotherapy in experimental liver metastases model of nude mouse. (6/2094)

The biodistribution and intratumoral distribution of radiolabeled anticarcinoembryonic antigen (CEA) monoclonal antibody in experimental liver metastases and the therapeutic effect of 131I-labeled anti-CEA antibody on the metastases were studied. METHODS: Three weeks after an intrasplenic injection of human colon cancer cells, mice received an intravenous injection of 125I- or 111In-labeled anti-CEA antibody F33-104. The biodistribution and tumor penetration of radiolabeled antibody were examined by using quantitative autoradiography. To evaluate the therapeutic effect, 5.55, 9.25 or 11.1 MBq (150, 250 or 300 microCi) 131I-labeled F33-104 were injected into groups of mice that had micrometastases smaller than 1 mm. Control groups were injected with phosphate-buffered saline or 131I-labeled control antibody. Mice were killed 3 wk later to determine the size of liver metastases. RESULTS: 1251-labeled F33-104 showed a high accumulation in the liver metastases (percentage of injected dose per gram of metastases [%ID/g] >24%, metastasis-to-liver ratio >9.8, metastasis-to-blood ratio >2.1); however, its accumulation was heterogeneous or peripheral in the nodules more than 1 mm in diameter. When the antibody dose was increased, antibody penetration was improved, but tumor uptake of radioactivity and specificity ratios decreased. In mice with large metastases, radioactivity in the normal tissue was lower than that in mice with small metastases, resulting in higher metastasis-to-background ratios. 111In-labeled antibody showed even higher tumor uptake than 125I-labeled antibody (>51 %ID/g). Metastases formation was suppressed in a dose-dependent manner by 131I-labeled F33-104 injection (5 of 8 mice had no macroscopic tumor after an injection of 5.55 MBq (150 microCi), and all mice had no visible metastasis after an injection of 9.25 or 11.1 MBq [250 or 300 microCi]), whereas tumor progression was seen in the control groups. CONCLUSION: Liver metastases had easy accessibility to the antibody. Micrometastases of less than 0.5 mm in diameter showed homogeneous intratumoral distribution of injected antibody and were successfully treated with 131I-labeled antibody. Very high uptake and satisfactory metastasis-to-liver ratios with 111In-labeled antibody suggest that the use of a radiometal with high beta-energy, such as 90Y or 188Re, is preferable for the successful radioimmunotherapy of metastases larger than 1 mm.  (+info)

Gastroenteropancreatic neuroendocrine tumor metastases to the thyroid gland: differential diagnosis with medullary thyroid carcinoma. (7/2094)

Neuroendocrine tumors (NET) of the thyroid gland are rare. Apart from medullary thyroid carcinoma (MTC), metastases of gastroenteropancreatic (GEP) NET may also occur. Features of six patients (five men, one female: age range, 39-67 years) with thyroid metastases from a GEP-NET are described. Thyroid metastases were bilateral in all patients and were associated with enlarged neck lymph nodes in five. In four cases, the thyroid tumor was either the first sign of the disease (n = 2) or was an isolated site of recurrence (n = 2). The tumors were well (n = 3) or poorly differentiated (n = 3). Five tumors for which the primary site could be determined corresponded to foregut-derived tumors (3 lungs, 1 thymus and 1 pancreatic NET). One tumor demonstrated calcitonin (CT) production as shown by immunohistochemistry and elevated plasma CT levels. However, the disease history and the clinical features strongly favored a metastasizing GEP-NET. No tumoral RET proto-oncogene mutation was found in this patient. The differential diagnosis between metastatic GEP-NET and MTC is crucial because prognosis, work-up, and treatment differ greatly.  (+info)

Roles of circulating carcinoembryonic antigen and calcitonin in diagnosis of medullary thyroid carcinoma: a comparative study. (8/2094)

Carcinoembryonic antigen (CEA) and calcitonin (CT) were simultaneously determined in sera and tumor tissues from 15 patients with medullary carcinoma of the thyroid (MCT). Serum CEA was increased in all but one patient, and CT did in all of them. Both levels were significantly related to the weight of excised tumor, but not to the presence of metastasis. Furthermore, a significant correlation was noted between the basal levels of CT and CEA. Both levels fell to normal after a radical operation had been performed. Tissue concentrations of CEA and CT in the MCT were more than 100 times those in hyperthyroidism, and the ratios of tissue over serum levels averaged 770 in CEA and 1000 in CT. In the calcium infusion test, CEA levels were not significantly changed in contrast with a distinct increase in CT levels. The results indicate that CEA and CT represent separate activities of the tumor cells, and that circulating CEA together with CT is a useful indicator in the diagnosis and follow-up of the disease.  (+info)

*Carcinoembryonic antigen

In humans, the carcinoembryonic antigen family consists of 29 genes, 18 of which are normally expressed. The following is a ... Carcinoembryonic Antigen at the US National Library of Medicine Medical Subject Headings (MeSH) CEA at Lab Tests Online CEA: ... Carcinoembryonic antigen (CEA) describes a set of highly related glycoproteins involved in cell adhesion. CEA is normally ... Ballesta, AM; Molina, R; Filella, X; Jo, J; Giménez, N (1995). "Carcinoembryonic antigen in staging and follow-up of patients ...

*Carcinoembryonic antigen peptide-1

... is a nine amino acid peptide fragment of carcinoembryonic antigen (CEA), a protein that is ... Synonyms: CAP-1 Carcinoembryonic Antigen Peptide-1 Carcinoembryonic Peptide-1 CEA Peptide 1 CEA Peptide 9-mer National Cancer ...

*Spectrum bias

Fletcher RH (1986). "Carcinoembryonic antigen". Ann. Intern. Med. 104 (1): 66-73. doi:10.7326/0003-4819-104-1-66. PMID 3510056 ... the sensitivity and specificity change between different sub-groups of patients may be found with the carcinoembryonic antigen ...

*Tumor antigen

Oncofetal antigens are another important class of tumor antigens. Examples are alphafetoprotein (AFP) and carcinoembryonic ... mutant protein antigens, oncogenic viral antigens, cancer-testis antigens and vascular or stromal specific antigens. Tissue ... and some viral antigens are also cancer antigens. Cancer-testis antigens are antigens expressed primarily in the germ cells of ... Certain tumor antigens are thus used as tumor markers. More importantly, tumor antigens can be used in cancer therapy as tumor ...

*H19 (gene)

... the nonspecific cross-reacting antigen of carcinoembryonic antigen". Cancer Res. 57 (24): 5460-4. PMID 9407950. Kawaharata H, ... p95, or NCA-90, is related to carcinoembryonic antigens, which have been found to reduce drug toxicity by Kawaharata et al. NCI ... Hinoda Y, Itoh F, Endo T, Oikawa S, Nakazato H, Imai K (July 1997). "Decreased sensitivity of carcinoembryonic antigen cDNA- ...

*CEACAM5

Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) also known as CD66e (Cluster of Differentiation 66e), is a ... 1987). "Carcinoembryonic antigen family: expression in a mouse L-cell transfectant and characterization of a partial cDNA in ... Boehm MK, Perkins SJ (2000). "Structural models for carcinoembryonic antigen and its complex with the single-chain Fv antibody ... 2001). "Heterogeneous RNA-binding protein M4 is a receptor for carcinoembryonic antigen in Kupffer cells". J. Biol. Chem. 276 ( ...

*CEACAM8

Carcinoembryonic antigen-related cell adhesion molecule 8 (CEACAM8) also known as CD66b (Cluster of Differentiation 66b), is a ... 2002). "Carcinoembryonic antigen-related cell adhesion molecule 1 expression and signaling in human, mouse, and rat leukocytes ... 1992). "Identification of three new genes and estimation of the size of the carcinoembryonic antigen family". Genomics. 14 (2 ... 1991). "A specific heterotypic cell adhesion activity between members of carcinoembryonic antigen family, W272 and NCA, is ...

*CEACAM7

Carcinoembryonic antigen-related cell adhesion molecule 7 is a protein that in humans is encoded by the CEACAM7 gene. ... "Entrez Gene: CEACAM7 carcinoembryonic antigen-related cell adhesion molecule 7". Human CEACAM7 genome location and CEACAM7 gene ... 2000). "Carcinoembryonic antigen family members CEACAM6 and CEACAM7 are differentially expressed in normal tissues and ... 1989). "Analysis of the size of the carcinoembryonic antigen (CEA) gene family: isolation and sequencing of N-terminal domain ...

*Health effects of tobacco

better source needed] Sajid KM, Chaouachi K, Mahmood R (2008). "Hookah smoking and cancer: carcinoembryonic antigen (CEA) ... Carcinoembryonic antigen (CEA) is a marker found in several forms of cancer. Levels in exclusive hookah smokers were lower ...

*CEACAM1

... and a member of the carcinoembryonic antigen (CEA) gene family. This gene encodes a member of the carcinoembryonic antigen (CEA ... "Immunochemical analysis of carcinoembryonic antigen (CEA)-related antigens differentially localized in intracellular granules ... Carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) (CEACAM1) also known as CD66a (Cluster of ... Carcinoembryonic antigen Cluster of differentiation GRCh38: Ensembl release 89: ENSG00000079385 - Ensembl, May 2017 GRCm38: ...

*Kohzoh Imai

"Immunologic characterization and molecular profile of carcinoembryonic antigen detected by monoclonal antibodies". J Immunol. ... He is well known for the discovery of a melanoma-related antigen (later, it is called, Chondroitin Sulfate Proteoglycan-4 ( ... Imai K, Ng AK, Ferrone S (1981). "Characterization of monoclonal antibodies to human melanoma-associated antigens". J Natl ...

*PSG1 (gene)

These genes belong to a specific gene family; they are a subgroup of the carcinoembryonic antigen (CEA) family of genes. CEAs ... Khan WN, Hammarström S (1989). "Carcinoembryonic antigen gene family: molecular cloning of cDNA for a PS beta G/FL-NCA ... Khan WN, Osterman A, Hammarström S (May 1989). "Molecular cloning and expression of cDNA for a carcinoembryonic antigen-related ... Zoubir F, Khan WN, Hammarström S (May 1990). "Carcinoembryonic antigen gene family members in submandibular salivary gland: ...

*CEACAM3

... is a member of the carcinoembryonic antigen (CEA) gene family.. This gene encodes a member of the family of carcinoembryonic ... Carcinoembryonic antigen-related cell adhesion molecule 3 (CEACAM3) also known as CD66d (Cluster of Differentiation 66d), ... 1989). "Analysis of the size of the carcinoembryonic antigen (CEA) gene family: isolation and sequencing of N-terminal domain ... 1992). "Identification of three new genes and estimation of the size of the carcinoembryonic antigen family". Genomics. 14 (2 ...

*Mu'assel

Sajid, Khan; Chaouachi, Kamal; Mahmood, Rubaida (May 24, 2008). "Hookah smoking and cancer: carcinoembryonic antigen (CEA) ...

*Microglandular hyperplasia

Speers WC, Picaso LG, Silverberg SG (1983). "Immunohistochemical localization of carcinoembryonic antigen in microglandular ...

*Hookah

"Full text , Hookah smoking and cancer: carcinoembryonic antigen (CEA) levels in exclusive/ever hookah smokers". Harm Reduction ...

*Thymidine kinase

... carcinoembryonic antigen) and AFP (alpha fetoprotein). The genes for these tumor markers may be used as promoter genes for ... "Exposed proliferation antigen 210 (XPA-210) in renal cell carcinoma (RCC) and oncocytoma: clinical utility and biological ... cytosolic thymidine kinase as compared to proliferating cell nuclear antigen in patients with colorectal carcinoma". Anticancer ... immunohistochemical detection of cytosolic thymidine kinase and proliferating cell nuclear antigen in breast cancer". Cancer ...

*CD31

... a putative intercellular adhesion molecule closely related to carcinoembryonic antigen". J. Exp. Med. 171 (6): 2147-52. doi: ... Human CD Antigen Chart (eBioscience) Mouse CD Antigen Chart (eBioscience) Human PECAM1 genome location and PECAM1 gene details ... Malignant endothelial cells also commonly retain the antigen, so that CD31 immunohistochemistry can also be used to demonstrate ...

*Technetium (99mTc) arcitumomab

"Immunological heterogeneity of carcinoembryonic antigen: antigenic determinants on carcinoembryonic antigen distinguished by ... Arcitumomab recognizes carcinoembryonic antigen (CEA), an antigen over-expressed in 95% of colorectal cancers. Consequently, ... anti-carcinoembryonic antigen antibodies labeled with 99mTc: the role of metabolism and kinetics". Cancer Research. 55 (23 ... Cells in Colorectal Cancer Patients by Nested Reverse Transcription-Polymerase Chain Reaction for Carcinoembryonic Antigen ...

*Reference ranges for blood tests

Carcinoembryonic Antigen(CEA) at MedicineNet Basuyau JP, Mallet E, Leroy M, Brunelle P (October 2004). "Reference intervals for ... June 2008). "Reference intervals for carcinoembryonic antigen (CEA), CA125, MUC1, Alfa-foeto-protein (AFP), neuron-specific ...

*Oncofetal antigen

Another example is carcinoembryonic antigen, which is elevated in people with colon cancer and other tumors. Other oncofetal ... also known as oncofetal antigen protein). Oncofetal antigens are promising targets for vaccination against several types of ... Oncofetal antigens are proteins which are typically present only during fetal development but are found in adults with certain ... One example of an oncofetal antigen is alpha-fetoprotein, which is produced by hepatocellular carcinoma and some germ cell ...

*Medullary thyroid cancer

A second marker, carcinoembryonic antigen (CEA), also produced by medullary thyroid carcinoma, is released into the blood and ... The prognostic value of measuring calcitonin and carcinoembryonic antigen (CEA) concentrations in the blood was studied in 65 ... "Prognostic Impact of Serum Calcitonin and Carcinoembryonic Antigen Doubling-Times in Patients with Medullary Thyroid Carcinoma ... "Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma ...

*Thyroid cancer

"Prognostic Impact of Serum Calcitonin and Carcinoembryonic Antigen Doubling-Times in Patients with Medullary Thyroid Carcinoma ...

*PSG2

Zoubir F, Khan WN, Hammarström S (May 1990). "Carcinoembryonic antigen gene family members in submandibular salivary gland: ... and the carcinoembryonic antigen (CEA)-related proteins are members of the same multigene family". Biochemical and Biophysical ... "Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and ...

*CEACAM6

Carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) (CEACAM6) also known as CD66c ( ... 1988). "Primary structure of nonspecific crossreacting antigen (NCA), a member of carcinoembryonic antigen (CEA) gene family, ... CEACAM6 carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen)". Oikawa S, Inuzuka C, ... 2002). "Carcinoembryonic antigen-related cell adhesion molecule 1 expression and signaling in human, mouse, and rat leukocytes ...

*List of immunologists

... discovered Carcinoembryonic antigen Jules T. Freund (1890-1960) Sankar Ghosh John Grange Waldemar Haffkine (1860-1930), first ... isolation and partial characterization of A and B blood antigens Jian Zhou (1957-1999), with co-inventor Ian Frazer has ...
[54 Pages Report] Check for Discount on Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H1 2016 report by Global Markets Direct. Global Markets Directs, Carcinoembryonic Antigen-Related Cell Adhesion Molecule...
Carcinoembryonic antigen-related cell adhesion molecule 7 is a protein that in humans is encoded by the CEACAM7 gene. ENSG00000007306 GRCh38: Ensembl release 89: ENSG00000280501, ENSG00000007306 - Ensembl, May 2017 "Human PubMed Reference:". Thompson J, Zimmermann W, Nollau P, Neumaier M, Weber-Arden J, Schrewe H, Craig I, Willcocks T (Jan 1995). "CGM2, a member of the carcinoembryonic antigen gene family is down-regulated in colorectal carcinomas". J Biol Chem. 269 (52): 32924-31. PMID 7806520. Thompson J, Seitz M, Chastre E, Ditter M, Aldrian C, Gespach C, Zimmermann W (May 1997). "Down-regulation of carcinoembryonic antigen family member 2 expression is an early event in colorectal tumorigenesis". Cancer Res. 57 (9): 1776-84. PMID 9135022. "Entrez Gene: CEACAM7 carcinoembryonic antigen-related cell adhesion molecule 7". Human CEACAM7 genome location and CEACAM7 gene details page in the UCSC Genome Browser. Douard R, Wind P, Sales JP, et al. (2006). "Long-term prognostic value of detection of ...
Carcinoembryonic antigen-related cell adhesion molecule 8 (CEACAM8) also known as CD66b (Cluster of Differentiation 66b), is a member of the carcinoembryonic antigen (CEA) gene family. Its main function is cell adhesion, cell migration, and pathogen binding. CEACAM8 is expressed exclusively on granulocytes and used as granulocyte marker. Cluster of differentiation GRCh38: Ensembl release 89: ENSG00000124469 - Ensembl, May 2017 "Human PubMed Reference:". "Entrez Gene: CEACAM8 carcinoembryonic antigen-related cell adhesion molecule 8". Khan WN, Frängsmyr L, Teglund S, et al. (1992). "Identification of three new genes and estimation of the size of the carcinoembryonic antigen family". Genomics. 14 (2): 384-90. doi:10.1016/S0888-7543(05)80230-7. PMID 1427854. Oikawa S, Inuzuka C, Kuroki M, et al. (1991). "A specific heterotypic cell adhesion activity between members of carcinoembryonic antigen family, W272 and NCA, is mediated by N-domains". J. Biol. Chem. 266 (13): 7995-8001. PMID 2022629. Berling ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Looking for carcinoembryonic antigen? Find out information about carcinoembryonic antigen. A glycoprotein found in tissues of the fetal gut during the first two trimesters of pregnancy and in the peripheral blood of individuals with some forms of... Explanation of carcinoembryonic antigen
TY - JOUR. T1 - Immunohistochemical detection of carcinoembryonic antigen and P-glycoprotein in small cell lung cancer at diagnosis and relapse, with special reference to the tissue expression of CEA and response to chemotherapy. AU - Ohnoshi, T.. AU - Ueoka, H.. AU - Segawa, Y.. AU - Kiura, Katsuyuki. AU - Tabata, Masahiro. AU - Shibayama, T.. AU - Maeda, T.. AU - Miyatake, M.. AU - Takigawa, N.. AU - Kimura, I.. PY - 1992. Y1 - 1992. N2 - Small cell lung cancer (SCLC) is one of the most sensitive tumors to drug therapy; however, the majority of patients eventually relapse within a few years. Emergence of drug resistance is thought to play a major role in the dismal course of this disease. However, the mechanism of drug resistance in SCLC still remains obscure. Based on the clinical observation that a significant proportion of patients with relapsing tumor show an elevated serum carcinoembryonic antigen (CEA) concentration while serum neuron-specific enolase (NSE) concentration remains normal, ...
The Development of a Radioimmuno-Assay for Carcino-Embryonic Antigen with some Applications. Clinical Evaluation of Cercino-Ernbryonic Antigen, ...
BACKGROUND: Expansions of gene families are predictive for ongoing genetic adaptation to environmental cues. We describe such an expansion of the carcinoembryonic antigen (CEA) gene family in certain bat families. Members of the CEA family in humans and mice are exploited as cellular receptors by a number of pathogens, possibly due to their function in immunity and reproduction. The CEA family is composed of CEA-related cell adhesion molecules (CEACAMs) and secreted pregnancy-specific glycoproteins (PSGs). PSGs are almost exclusively expressed by trophoblast cells at the maternal-fetal interface. The reason why PSGs exist only in a minority of mammals is still unknown. RESULTS: Analysis of the CEA gene family in bats revealed that in certain bat families, belonging to the subgroup Yangochiroptera but not the Yinpterochiroptera subgroup an expansion of the CEA gene family took place, resulting in approximately one hundred CEA family genes in some species of the Vespertilionidae. The majority of ...
The NK killing activity is regulated by activating and inhibitory NK receptors. All of the activating ligands identified so far are either viral or stress-induced proteins. The class I MHC proteins are the ligands for most of the inhibitory NK receptors. However, in the past few years, several receptors have been identified that are able to inhibit NK killing independently of class I MHC recognition. We have previously demonstrated the existence of a novel inhibitory mechanism of NK cell cytotoxicity mediated by the homophilic carcinoembryonic Ag (CEA)-related cell adhesion molecule 1 (CEACAM1) interactions. In this study, we demonstrate that CEACAM1 also interacts heterophilically with the CEA protein. Importantly, we show that these heterophilic interactions of CEA and CEACAM1 inhibit the killing by NK cells. Because CEA is expressed on a wide range of carcinomas and commonly used as tumor marker, these results represent a novel role for the CEA protein enabling the escape of tumor cells from NK
TY - JOUR. T1 - The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients. T2 - data from the Korean Breast Cancer Society Registry. AU - Nam, Sang eun. AU - Lim, Woosung. AU - Jeong, Joon. AU - Lee, Seeyoun. AU - Choi, Jungeun. AU - Park, Heung Kyu. AU - Jung, Yong Sik. AU - Jung, Seung Pil. AU - Bae, Soo Youn. PY - 2019/1/1. Y1 - 2019/1/1. N2 - Purpose: Tumor markers such as carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) are widely used for monitoring breast cancer. However, the prognostic efficacy of preoperative elevations of CEA and CA15-3 levels in breast cancer patients remains controversial. Methods: We retrospectively analyzed the clinicopathological parameters of 149,238 patients in the Korean Breast Cancer Society Registry Database who underwent surgery between January 2000 and December 2015. Results: The patients with elevated CA15-3/CEA levels had worse overall survival (OS) than the patients with normal CA15-3/CEA ...
Carcinoembryonic antigen (CEA) is a glycosylphosphatidylinositol (GPI)-cell surface anchored glycoprotein, first identified in tissue extracts from human colon tumors. The CEA family of genes is part of the immunoglobulin superfamily. In humans, the CEA family consists of 29 genes, 18 of which are normally expressed only during fetal development. Therefore, CEA is not detectable in the blood of healthy adults, but CEA expression is observed in many types of cancer ...
Carcinoembryonic antigen (CEA) is a glycosylphosphatidylinositol (GPI)-cell surface anchored glycoprotein, first identified in tissue extracts from human colon tumors. The CEA family of genes is part of the immunoglobulin superfamily. In humans, the CEA family consists of 29 genes, 18 of which are normally expressed only during fetal development. Therefore, CEA is not detectable in the blood of healthy adults, but CEA expression is observed in many types of cancer ...
The latest market report published by Credence Research, Inc. "Global Carcinoembryonic Antigen (CEA) Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 - 2023," the carcinoembryonic antigen (CEA) market was valued at USD 1,624.2 Mn in 2015, and is expected to reach USD 2,787.3 Mn by 2023, expanding at a CAGR of 6.4% from 2016 to 2023.. Market Insights. According to Quest Diagnostics, CEA is an oncofetal glycoprotein present in the gastrointestinal tract and body fluids of the embryo and fetus. This antigen is also present in certain adult gastrointestinal cells, including the mucosal cells of the colorectum, and small amounts are present in blood. Market experts suggest that key growth drivers assisting the growth of CEA market comprises high prevalence of cancer, mounting global geriatric population base, high demand for minimally invasive diagnostic procedures in cancer and increasing application of CEA for diagnosis at several stages of cancer. In addition, a few ...
Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis Qingcai Meng,1–3,* Si Shi,1–3,* Chen Liang,1–3,* Dingkong Liang,1–3 Wenyan Xu,1–3 Shunrong Ji,1–3 Bo Zhang,1–3 Quanxing Ni,1–3 Jin Xu,1–3 Xianjun Yu1–3 1Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, 2Department of Oncology, Shanghai Medical College, 3Pancreatic Cancer Institute, Fudan University, Shanghai, People’s Republic of China *These authors contributed equally to this work Background: Carcinoembryonic antigen (CEA) is one of the most widely used tumor markers and is increased in 30%–60% of patients with pancreatic cancer. Although carbohydrate antigen 19-9 (CA19-9) is the most important serum biomarker in pancreatic cancer, the diagnostic and prognostic value of CEA is gradually being recognized.Materials and methods: The MEDLINE, EMBASE, and Web of Science databases were
... Carcinoembryonic antigen (CEA) is a glycoprotein involved in cell adhesion. It is normally produced during fetal development, but the production of CEA stops before birth.
TY - JOUR. T1 - Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. AU - Nukaya, I.. AU - Yasumoto, M.. AU - Iwasaki, T.. AU - Ideno, M.. AU - Sette, A.. AU - Celis, E.. AU - Takesako, K.. AU - Kato, I.. PY - 1999/1/5. Y1 - 1999/1/5. N2 - Carcinoembryonic antigen (CEA), which is expressed in several cancer types, is a potential target for specific immunotherapy. HLA-A24 is the most frequent allele among Japanese and is also frequently present in Asians and Caucasians. We tested CEA-encoded HLA-A24 binding peptides for their capacity to elicit anti-tumor cytotoxic T lymphocytes (CTL) in vitro. For this purpose, we used CD8+ T lymphocytes from peripheral blood mononuclear cells (PBMC) of a healthy donor and autologous peptide-pulsed dendritic cells as antigen-presenting cells. This approach enabled us to identify 2 peptides, QYSWFVNGTF and TYACFVSNL, which were capable of eliciting CTL lines that lysed tumor cells expressing ...
Free Online Library: France - CARCINOEMBRYONIC ANTIGEN. by Mena Report; Business, international Carcinoembryonic antigen CEA (Oncology)
In the present study we describe the establishment and characteristics of a new human tumor cell line (OV-1063) positive for carcinoembryonic antigen (CEA) originating from ovarian metastatic tumor cells. Analysis of the cultured cells during their in vitro adaptation period revealed while the primary culture exhibited a low proportion of CEA-positive cells, this proportion increased with culture passages and eventually more than 90% of the cells in the established line were CEA-positive. Thus, during the period of adaptation to in vitro growth, a selection for CEA-positive cells took place but the amount of CEA secreted per each positive cell seemed to be constant. Several tumor-associated characteristics were found positive on the established OV-1063 cell line. The in vitro growing cell line exhibited an abnormal chromosome pattern with a near-trisomy karyotype for some chromosomes, colony formation in soft agar as well as positive staining with a monoclonal antibody B38.1. Culture supernatants of the
Mouse monoclonal antibody raised against full length recombinant human Carcinoembryonic Antigen (CEA). Recombinant protein corresponding to full length human Carcinoembryonic Antigen. (MAB14723) - Products - Abnova
Increased serum CEA levels have been detected in persons with primary colorectal cancer and in patients with other malignancies involving the gastrointestinal tract, breast, lung, ovarian, prostatic, liver and pancreatic cancers. Elevated serum CEA levels have also been detected in patients with nonmalignant disease, especially patients who are older or who are smokers. CEA levels are not useful in screening the general population for undetected cancers. However, CEA levels provide important information about patient prognosis, recurrence of tumors after surgical removal, and effectiveness of therapy. ...
A novel magnetic nanoparticle-based electrochemical immunoassay of carcinoembryonic antigen (CEA) was designed as a model using CEA antibody-functionalized magnetic beads [DNA/Fe3O4/ZrO2; Fe3O4 (core)/ZrO2 (shell) nano particles (ZMPs)] as immunosensing probes. To design the immunoassay, the CEA antibody and O-phenylenediamine (OPD) were initially immobilized on a chitosan/nano gold composite membrane on a glassy carbon electrode (GCE/CS-nano Au), which was used for CEA recognition. Then, horseradish peroxidase (HRP)-labeled anti-CEA antibodies (HRP-CEA Ab2) were bound to the surface of the synthesized magnetic ZMP nanoparticles as signal tag. Thus, the sandwich-type immune complex could be formed between secondary antibody (Ab2) modified DNA/ZMPs nanochains tagged by HRP and GCE/CS-nano Au. Unlike conventional nanoparticle-based electrochemical immunoassays, the recognition elements of this immunoassay included both electron mediators and enzyme labels, which obviously simplifies the electrochemical
The global carcinoembryonic antigen (CEA) market is segmented on the basis of application type into ovarian cancer, colorectal cancer, pancreatic cancer, lung cancer, breast cancer, thyroid cancer and other cancers. In base year 2015, colorectal cancer dominated the overall market in terms of revenue. The key factors responsible for growth of CEA market are increase in number of population consuming alcohol, sedentary lifestyle, and high intake of saturated fats in all age groups. Moreover, rising preference for CEA test in cancer diagnosis and management is expected to assist its market growth in the near future.. In base year 2015, North America was observed as the largest CEA market due to high public awareness related to early cancer diagnosis, rising preference for minimally invasive cancer diagnosis tests and sophisticated health care facilities for cancer management. Incessant technological developments followed by new discoveries of specific antigens and biomarkers are anticipated to ...
CEA is a large glycoprotein (~200 kD) consisting of a single polypeptide chain with varying carbohydrate components. Elevated CEA levels can be detected in smokers, patients with colorectal polyps, pancreatitis, liver disease, pulmonary infectious, inflammatory bowel disease and renal failure. Clinically, CEA is used to determine tumor recurrence post-operatively following resection of colon carcinoma.
Tumor markers play an important role in the identification of human malignancies. It has been shown that the carcinoembryonic antigen (CEA, CEACAM5) is a promoter of metastasis in epithelial cancers that is widely used as a clinical marker. The aim of this study is to elucidate the network of genes that are involved in the CEA-induced liver metastasis. Previously, we have shown that CEA is accumulated in the lungs and livers of rats by interacting with their macrophages. We identified and cloned a new gene (CEAR) for the CEA-binding protein, which is located on the surface of fixed liver macrophages, Kupffer cells (Bajenova et al, 2001). It has been shown that the interaction of CEA and CEAR proteins increases the production of IL-1, IL-10, IL-6, TNF-α cytokines (Thomas et al, 2011). This interaction changes the expression of liver adhesion molecules that enhances the survival of cancer cells to the liver. We also suggested that CEA synthesis by cancer cells may influence the E-cadherin adhesion
Carcinoembryonic Antigen (CEA) / CD66 Antibody - Without BSA and Azide, Mouse Monoclonal Antibody [Clone SPM551 ] validated in IHC-P, IF, FC (AH10385-100), Abgent
Carcinoembryonic antigen (CEA) answers are found in the Guide to Diagnostic Tests powered by Unbound Medicine. Available for iPhone, iPad, Android, and Web.
Global carcinoembryonic antigen market value surpassed USD 1.9 billion in 2017 and is expected to witness more than 6.7% CAGR from 2018 to 2024 owing to increasing incidences for cancer disease, especially colorectal cancer.
In this study, a sandwich-type electrochemical (EC) immunosensor was proposed to detect a carcinoembryonic antigen (CEA) based on Au-graphene and [email protected] blue (MB). The Au nanoparticles (NPs)-vertical graphene (VG) electrode efficiently amplifies the response signal by immobilizing a large amount of the c
Definition Carcinoembryonic antigen (CEA) is an antigen (protein) present in very small quantities in adult tissue. A greater than normal amount may be suggestive of cancer. Normally, its values range
This test measures a protein called carcinoembryonic antigen (CEA) in your blood. This protein is present on some types of cancer cells.
This test measures a protein called carcinoembryonic antigen (CEA) in your blood. This protein is present on some types of cancer cells.
This test measures a protein called carcinoembryonic antigen (CEA) in your blood. This protein is present on some types of cancer cells.
This test measures a protein called carcinoembryonic antigen (CEA) in your blood. This protein is present on some types of cancer cells.
Based on previous experiments in nude mice, showing that fluoresceinated monoclonal antibodies against carcinoembryonic antigen localized specifically in human carcinoma xenografts and could be detected by laser-induced fluorescence, we performed a feasibility study to determine whether this immunophotodiagnosis method could be applied in the clinic. Six patients, with known primary colorectal carcinoma, received an i.v. injection of 4.5 or 9 mg of mouse-human chimeric anti-carcinoembryonic antigen monoclonal antibody coupled with 0.10-0.28 mg of fluorescein (molar ratio 1/10 to 1/14). The monoclonal antibody was also labeled with 0.2-0.4 mCi of 125I (1 Ci = 37 GBq). Photodetection of the tumor was done ex vivo on surgically resected tissues for the six patients and in vivo by fluorescence rectosigmoidoscopy for the sixth patient. Upon laser irradiation, clearly detectable heterogeneous green fluorescence from the dye-antibody conjugate was visually observed on all six tumors; almost n
Clone REA428 recognizes an epitope shared by the human CD66a, c, d, and e antigens, which are also known as the human carcinoembryonic antigen (CEA) family. The CEA family has 7 genes belonging to the CEACAM subgroup. These subgroup members are mainly associated with the cell membrane and show a complex expression pattern in normal and cancerous tissues. CD66a (CEACAM1) is an adhesion molecule that is involved in many immune responses associated with infection, inflammation, and cancer. It interacts homophilically with CD66a and heterophilically with CD66e (CEACAM5), but not with other CEACAM proteins. CD66a is expressed on a variety of cells, e.g., some epithelial cells, melanoma, and activated lymphocytes. Within the hematopoietic system, CD66c (CEACAM6) expression is limited to granulocytes and its precursors, where it serves homotypic and heterotypic adhesion and Ca2+ mediated signaling. It is markedly upregulated from intracellular stores after activatio and is also found in epithelia of various
Recombinant human monoclonal antibody raised against human carcinoembryonic antigen (CEA). Original antibody is raised against native purified human CEA. (RAB00036) - Products - Abnova
A carcinoembryonic antigen (CEA) test is used to check how well treatment is working in certain types of cancer, particularly colon cancer.. Carcinoembryonic antigens are harmful substances (usually proteins) that are produced by some types of cancer. In response to the antigens, the body produces antibodies to help fight them.. A CEA test is often carried out after surgery to check carcinoembryonic antigen levels.. As well as being a useful marker in cases of colon cancer, CEA tests can also be used to assess other types of cancer including:. ...
The aim of the present prospective study was to investigate the fluorescence emission of human blood plasma of patients with colorectal cancer.. For years, serum tumor markers have been studied for the diagnosis and follow-up of colorectal cancer, among which carcinoembryonic antigen (CEA) has achieved promising results. However, the sensitivity of CEA for colorectal cancer is less than 25% and elevated CEA levels also occur in patients with benign disease, as well as in patients with other carcinomas. Nevertheless, surveillance programs are often based on the CEA test and combination with other markers is at present a matter of research. Alternative methods based on optical fluoroscopy have been introduced in experimental stages for clinical diagnosis of cancer. Few studies have been reported on the application of native fluorescence spectroscopy of biofluids in the diagnosis of tumoral diseases. The above reported findings prompted us to investigate the fluorescence emission of human blood ...
The aim of the present prospective study was to investigate the fluorescence emission of human blood plasma of patients with colorectal cancer.. For years, serum tumor markers have been studied for the diagnosis and follow-up of colorectal cancer, among which carcinoembryonic antigen (CEA) has achieved promising results. However, the sensitivity of CEA for colorectal cancer is less than 25% and elevated CEA levels also occur in patients with benign disease, as well as in patients with other carcinomas. Nevertheless, surveillance programs are often based on the CEA test and combination with other markers is at present a matter of research. Alternative methods based on optical fluoroscopy have been introduced in experimental stages for clinical diagnosis of cancer. Few studies have been reported on the application of native fluorescence spectroscopy of biofluids in the diagnosis of tumoral diseases. The above reported findings prompted us to investigate the fluorescence emission of human blood ...
Carcinoembryonic antigen (CEA) is a glycoprotein, which was first identified in patients with colonic carcinoma and in epithelial tumours of endodermal origin (gastrointestinal tract) by Gold and Freedman (1). The CEA molecule is quite heterogeneous due to the carbohydrate contents (50-60%) and depending on the purification procedure employed. It is soluble in perchloric acid and has a molecular weight of about 175.000-200.000 Daltons (2). Immunological and genetic characterization of CEA has identified a family of CEA-like molecules sharing common antigenic determinants. The most relevant CEA-like molecule is NCA (non-specific cross-reacting antigen) synthesized both by normal and pathological tissues. The problem of cross-reacting CEA-like molecules when assaying CEA is possible to overcome by the use of monoclonal antibodies. The CanAg CEA EIA is based on two mouse monoclonal antibodies against the Gold epitopes IV and V (3, 4 ...
Blood samples (5 mL) were drawn from the PV and tumor DV and placed in plain tubes. PV blood was obtained 1 hour prior to surgical incision. DV blood was obtained prior to the ligation of any branch of the SMV in patients with proximal colon cancer and prior to ligation of the IMV in patients with distal colon cancers. Samples were immediately centrifuged, and plasma and serum were separately stored at −70°C until analysis. enzyme-linked immunosorbent assay (ELISA) was performed using commercially available kits (IBL-Hamburg GmbH, Hamburg, Germany) according to manufacturers instructions. Diluted serum was transferred to wells of plates pre-coated with primary antibody. Following the recommended incubation period, plates were washed with buffer solution, and substrate solution was added and incubated as instructed. The wells were developed with a color-reagent. Stop solution was added to each well after incubation and the optical density was measured at a wavelength of 450 nm using automated ...
An Mr 110,000 antigen was initially described in human gastric carcinoma cells by its cross-reactivity with anti-carcinoembryonic antigen (CEA) monoclonal antibodies, as well as the ability of γ-interferon to increase its level of expression. We describe the molecular cloning and sequence analyses of overlapping clones that constitute a full-length complementary DNA that encodes for the entire Mr 110,000 molecule. The 1.5-kilobase message encodes for a 407-amino acid polypeptide whose structural analysis was consistent with an integral membrane glycoprotein. In particular, the extracellular domain was rich in serine and threonine residues at which carbohydrate substitution is likely through O- and N-linked glycosylation. This would explain the higher molecular weight of the antigen whose polypeptide backbone is approximately Mr 42,000. Further computer-aided sequence analyses revealed no significant homology with any member of the CEA gene family. The cross-reactivity with anti-CEA monoclonal ...
Only a few markers have been instrumental in the diagnosis of cancer. In contrast, tumor markers play a critical role in the monitoring of patients. The patients clinical status and response to treatment can be evaluated rapidly using the tumor marker half-life (t(1/2)) and the tumor marker doubling time (DT). This report reviews the interest of determining these kinetic parameters for prostate-specific antigen, human chorionic gonadotropin, alpha-fetoprotein, carcinoembryonic antigen, cancer antigen (CA) 125, and CA 15-3. A rise in tumor markers (DT) is a yardstick with which benign diseases can be distinguished from metastatic disease, and the DT can be used to assess the efficacy of treatments. A decline in the tumor marker concentration (t(1/2)) is a predictor of possible residual disease if the timing of blood sampling is soon after therapy. The discrepancies in results obtained by different groups may be attributable to the multiplicity of immunoassays, the intrinsic characteristics of each
Affiliation:自治医科大学,医学部,教授, Research Field:Laboratory medicine,Laboratory medicine,Collagenous pathology/Allergology,Orthopaedic surgery,Neurology, Keywords:アミロイドーシス,血清アミロイドA,HDL,SAA,炎症,単球,Carcinoembryonic antigen,Nonspecific cross-reacting antigen,臨床化学,表面プラズモン共鳴, # of Research Projects:15, # of Research Products:52, Ongoing Project:AAアミロイドの重合と組織沈着機構の解明
Aim: To investigate the clinical and pathological relevance of detection of circulating tumor cells (CTC) in the peripheral blood of gastric carcinoma patients before operation. Patients and Methods: Fifty patients with gastric adenocarcinoma were analysed prospectively. Patients were divided into two groups according to the extent of the tumor. Group I (unresectable) consisted of 22, and group II (resectable) consisted of 28 patients. Peripheral blood samples were collected pre-operatively from all 50 patients as well as from ten healthy controls and analyzed for carcinoembryonic antigen (CEA) and cytokeratin-19 (CK-19) messenger ribonucleic acids (mRNAs). Tumor localisation, stage, presence of signet cell formation, nodal metastases, serousal and lymphovascular invasion were recorded for all patients. Results: Expression of CK-19 was detected in 24 (48%), and CEA in 10 (20%) cases. Nine patients (40%) in group I and 15 (53.6%) in group II were positive for CK-19 expression. CEA expression was ...
The invention relates to murine/human chimeric monoclonal antibodies with high specificity to and affinity for human carcinoembryonic antigen (CEA), derivatives thereof, processes for the preparation of these antibodies and their derivatives, DNAs coding for heavy and light chains of these antibodies, processes for the preparation of said DNAs, mammalian cell lines that produce and secrete the antibodies and processes for the preparation of said cell lines. The chimeric antibodies and their derivatives are used for clinical purposes in vitro and in vivo, especially for the diagnosis of cancer, for localization and in vivo imaging of tumors, for therapy, e.g. site-directed delivery of cytotoxins, and similar purposes. The invention also concerns test kits and pharmaceutical compositions containing said chimeric monoclonal antibodies and/or derivatives thereof.
Thank you for your interest in spreading the word about Biochemical Society Transactions.. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.. ...
Background: The objective of the current study was to assess the impact of serum CA19-9 and CEA and their combination on survival among patients undergoing surgery for intrahepatic cholangiocarcinoma (ICC). Methods: Patients who underwent curative-intent resection of ICC between 1990 and 2016 were identified using a multi-institutional database. Patients were categorized into four groups based on combinations of serum CA19-9 and CEA (low vs. high). Factors associated with 1-year mortality after hepatectomy were examined. Results: Among 588 patients, 5-year OS was considerably better among patients with low CA19-9/low CEA (54.5%) compared with low CA19-9/high CEA (14.6%), high CA19-9/low CEA (10.0%), or high CA19-9/high CEA (0%) (P , 0.001). No difference in 1-year OS existed between patients who had either high CA19-9 (high CA19-9/low CEA: 70.4%) or high CEA levels (low CA19-9/high CEA: 72.5%) (P = 0.92). Although patients with the most favorable tumor marker profile (low CA19-9/low CEA) had the ...
CD66a/c/e are members of the CEA (carcinoembryonic antigen) family of the Ig superfamily. CEA family members are involved in transmembrane signaling and activation of neutrophils.
The purpose of this study is to find out which doses of the study drug are safe to give to patients with gastrointestinal (colon, liver, pancreas, stomach) solid tumors. The study drug is RO6958688. RO6958688 is an antibody that targets CEA on the tumor cells and may activate the immune system in targeting cancer cells. The study will also explore how the study drug works in the body and on the tumor. The study also wants to find out if RO6958688 can slow down the growth of tumors or stop the cancer.
The primary purpose of the study is to confirm the results of previous study about the usefulness of the serum Carcinoembryonic antigen (CEA) kinetic fo
A) Normal Human Keratinocytes on 3T3 Feeder Layer. Keratinocyte pancytokeratin stained green, and vimentin in 3T3 cells, red. ) (c) Breast Stromal Fibroblasts. Immunoperoxidase stained for vimentin (brown). ) (b) Human Glioma. MOG-G-CCM cells stained for GFAP by immunoperoxidase. (d) Human Umbilical Vein Endothelial cells. Factor VIII granular staining by immunoperoxidase. Plate 11. Immunostaining. (a) Dome Forming in Monolayer of Wil Lung Adenocarcinoma. Mosaic of CEA-positive and CEA-negative cells. Harrison [1907] chose the frog as his source of tissue, presumably because it was a cold-blooded animal, and consequently incubation was not required. Furthermore because tissue regeneration is more common in lower vertebrates, he perhaps felt that growth was more likely to 4 CULTURE OF ANIMAL CELLS 60000 Number of hits 50000 40000 30000 20000 10000 0 1960 Cumulative total [Fischer,1925] 1970 1980 1990 2000 2010 Pulication year Fig. 1. Growth of Tissue Culture. Number of hits in PubMed for cell ...
Background: Gallbladder carcinoma (GBC) sometimes presents with nonspecific signs, without forming a mass, mimicking benign gallbladder (GB) diseases. On the contrary, benign GB diseases may mimic GBC. Material and Methods: We retrospectively reviewed 107 cases over a period of 3 years (May 2012-April 2015), which included 41 review cases and 66 departmental cases. Carcinoembryonic antigen (CEA) immunomarker expression was done. Results: In 27 of the 41 review cases, the diagnoses were benign diseases of GB associated with mild-to-moderate dysplasia of mucosal glands; however, after review in our department, it was found that of these 27 cases, nine cases were actually well-differentiated adenocarcinoma of GB with diffuse CEA expression and were mis diagnosed as benign diseases of GB with dysplasia ...
The Test Is Based On The Principle Of Sandwich Immunoassay For Determination Of CEA In Serum. Monoclonal And Polyclonal Antibodies Are Employed To Identify CEA Specifically. This One Step Test Is Very...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
CEA-related cell adhesion molecules (CEACAM) belong to the carcinoembryonic antigen (CEA) family (1). It consists of seven CEACAM (CEACAM1,…
CEA has been a constant bane to me since my initial diagnosis in 2012. Preoperative CEA was 13.9. The lowest it dropped to was 3.11 when the clinic I went to used a lab that did the Siemans/Bayer assay test that had 0-3 as normal for non smokers and up to 5 for smokers. Before I switched clinics, the lab at this clinic changed assay methods and went with the Roche test. This changed the scale for what was considered normal. Depending on the lab, the new normal CEA level is anywhere from 4 to 5. Since then my blood work has been done with the Roche test which I only had one CEA test come in just below the normal limit. All my other blood work has come in between 5 to 6. This has been going on for the past 2 years.. Last year, during my normal checkup, CEA was run again and to my surprise....9.7. A retest was ordered to make sure that number was real....came back at 11. Ok. So whats going on? I had a CT with contrast done a few weeks prior to meeting up with my oncologist and having the CEA done. ...
We have previously shown that the colon carcinoma (LS174T) xenografts that emerged shortly after radioimmunotherapy with 90Y-labeled anti-CEA monoclonal antibody (MAb) ZCE025 lacked significant expression of CEA in comparison with the untreated tumors. The present study was designed to establish if the immunophenotype of the treated tumors was the result of CEA specific therapy and if the effect was permanent. Athymic mice bearing LS174T tumors were treated either with 120 µCi of 90Y-ZCE025, an equal dose of 90Y-96.5 (nonspecific MAb), or received no treatment. When the treated tumors grew to approximately 1.5 cm in diameter (6 weeks after therapy), they were resected and aliquoted to be transplanted to other mice, plated in tissue culture, fixed in formalin, and homogenized for CEA quantitation. The procedure was repeated 3 times (a total of 4 months after treatment). The CEA content was evaluated 2 and 6 weeks after therapy and when the tumors were transplanted. We confirmed a 4-fold decrease ...
This bachelor thesis is focused on the new tumor marker Fibroblast Growth Factor 23 (FGF 23) and its possible application in the diagnosis of colorectal carcinoma and its liver metastases. The goal of this thesis was to introduce the new automated chemiluminescent immunoassay (CLIA) method on the DiaSorin LIASON XL instrument to the determination of FGF 23. The main purpose of the FGF 23 introducing was to assess the level of FGF 23 in the normal population to obtain reference values and to assess level of FGF 23 in colorectal cancer patients and patients with the colorectal origin liver metastases. The evaluation included the comparison of the levels in the individual groups and comparison with already established tumor markers CEA, CA 19-9, TPA and TPS whose levels were determined in the same groups. According to the results of the FGF 23 assay by the CLIA method, FGF 23 reference values for the healthy population were set up at 30-105 pg/mL. In patients with colorectal cancer, the level of ...
The carcinoembryonic antigen, or CEA, levels of postoperative colon cancer patients are regularly checked by physicians as changes in the levels may indicate a relapse of the cancer. Relapse of other...
BACKGROUND: Intensive follow-up after surgery for colorectal cancer is common practice but lacks a firm evidence base. OBJECTIVE: To assess whether or not augmenting symptomatic follow-up in primary care with two intensive methods of follow-up [monitoring of blood carcinoembryonic antigen (CEA) levels and scheduled imaging] is effective and cost-effective in detecting the recurrence of colorectal cancer treatable surgically with curative intent. DESIGN: Randomised controlled open-label trial. Participants were randomly assigned to one of four groups: (1) minimum follow-up (n = 301), (2) CEA testing only (n = 300), (3) computerised tomography (CT) only (n = 299) or (4) CEA testing and CT (n = 302). Blood CEA was measured every 3 months for 2 years and then every 6 months for 3 years; CT scans of the chest, abdomen and pelvis were performed every 6 months for 2 years and then annually for 3 years. Those in the minimum and CEA testing-only arms had a single CT scan at 12-18 months. The groups were
Carcinoembryonic antigen (CEA) was purified from GW-39 human tumor xenografts in hamsters by immunoaffinity chromatography. Binding of the antigen to immobilized monoclonal antibody provided a high degree of purification of CEA in a single step. A recovery of 79% and a 750-fold purification were obtained. The purified CEA has a molecular size of 180 kilodaltons, an isoelectric point of 4.4, and a specific activity of 0.94. About 73% of the radiolabeled GW-39 CEA reacted with goat anti-CEA serum ...
CD4 (T4) is a single chain transmembrane glycoprotein and belongs to immunoglobulin supergene family. In extracellular region there are 4 immunoglobulin-like domains (1 Ig-like V-type and 3 Ig-like C2-type). Transmembrane region forms 25 aa, cytoplasmic tail consists of 38 aa. Domains 1,2 and 4 are stabilized by disulfide bonds. The intracellular domain of CD4 is associated with p56Lck, a Src-like protein tyrosine kinase. It was described that CD4 segregates into specific detergent-resistant T-cell membrane microdomains ...
CD4 is a single chain transmembrane glycoprotein and belongs to immunoglobulin supergene family. In extracellular region there are 4…
Complete information for CEACAM1 gene (Protein Coding), Carcinoembryonic Antigen Related Cell Adhesion Molecule 1, including: function, proteins, disorders, pathways, orthologs, and expression. GeneCards - The Human Gene Compendium
CD66b is a 95-100 kD glycosylphosphatidylinositol (GPI)-linked protein also known as CD67, CGM6, and NCA-95. CD66b is a member of the immunoglobulin superfamily, carcinoembryonic antigen (CEA)-like subfamily. CD66b, expressed on granulocytes, has been reported to induce activation in neutrophils and
CEACAM7 antibody (carcinoembryonic antigen related cell adhesion molecule 7) for IHC-P, WB. Anti-CEACAM7 pAb (GTX33089) is tested in Human, Mouse, Rat samples. 100% Ab-Assurance.
ETBX-011 is an investigational cancer vaccine being developed by Etubics to treat patients whose cancers express the protein carcinoembryonic antigen (CEA).
Mar 26, 2020, English Some insurers have added the carcinoembryonic antigen (CEA) blood test to the laboratory screening profile for Life and Health insurance applications, and some of our U.S. clients have asked for advice on whether to adopt this test. Every test has repercussions... Read More ...
Mar 26, 2020, English Some insurers have added the carcinoembryonic antigen (CEA) blood test to the laboratory screening profile for Life and Health insurance applications, and some of our U.S. clients have asked for advice on whether to adopt this test. Every test has repercussions... Read More ...
Immunohistochemistry examinations: (A) H&E (×100), (B) cytokeratin 7 (×100), (C) carcinoembryonic antigen (×100), (D) C-erb B2 (×100), (E) HMB-45 (×100
We describe a high-throughput screening system to detect interactions between leucocyte surface proteins, taking into account that these interactions are usually of very low affinity. The method involves producing the extracellular regions of leucocyte proteins with tags so that they can be bound to nanoparticles to provide an avid reagent to screen over an array of 36 similar proteins immobilized using the Proteon XPR36 with detection by surface plasmon resonance. The system was tested using established interactions that could be detected without spurious binding. The ability to detect new interactions was shown by identifying a new interaction between carcinoembryonic antigen-related cell adhesion molecule 1 and carcinoembryonic antigen-related cell adhesion molecule 8.
Build: Wed Jun 21 18:33:50 EDT 2017 (commit: 4a3b2dc). National Center for Advancing Translational Sciences (NCATS), 6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-435-0888. ...
0062]The SMI sensor was fabricated using 0.83 μM solution of CEA molecules and its sensitivity was tested using LoVo colorectal cancer cells which are known to secret a significant amount of CEA while dividing and growing [Drewinko B., Romsdahl M. M., Yang L. Y., Ahearn M. J., Trujillo J. M., Cancer Res. 1976, 36, 467]. FIG. 2A shows the response of the sensor as a function of CEA concentration in Hams F12K medium along with the sensor response as a function of the hemoglobin concentration, as well as the non-imprinted electrode response to the CEA. From the figure it can be seen that no response is obtained when placed in a solution of hemoglobin proteins or in a solution of CEA when the sensor was not imprinted. On the other hand, for the imprinted electrode the inventors observe a rapid increase in the potential for CEA concentrations below ˜165 ng/mL, followed by a more gradual increase at higher concentrations. This change in potential reflects an accumulation of the surface charge ...
Background: Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), an immunoglobulin (Ig)-related glycoprotein, serves as cellular receptor for a variety of Gram-negative bacterial pathogens associated with the human mucosa. In particular, Neisseria gonorrhoeae, N. meningitidis, Moraxella catarrhalis, and Haemophilus influenzae possess well-characterized CEACAM1-binding adhesins. CEACAM1 is typically involved in cell-cell attachment, epithelial differentiation, neovascularisation and regulation of T-cell proliferation, and is one of the few CEACAM family members with homologues in different mammalian lineages. However, it is unknown whether bacterial adhesins of human pathogens can recognize CEACAM1 orthologues from other mammals.,br /,Results: Sequence comparisons of the amino-terminal Ig-variable-like domain of CEACAM1 reveal that the highest sequence divergence between human, murine, canine and bovine orthologues is found in the β-strands comprising the bacteria-binding ...
Our previous in vitro data suggested that CEACAM1 is involved in angiogenesis. This is supported by a recent proteomic screen for cell membrane components expressed in newly formed tumor vessels and the fact that CEACAM1 expression is upregulated in synergy with other angiogenic factors in cardiac hypoxia (17, 19). To date, however, evidence for a causal implication of CEACAM1 in angiogenesis in vivo was lacking. In the present study, we report on 2 different genetic mouse models in which the angiogenic action of CEACAM1 has been investigated: in CEACAM1endo+ mice, the expression of CEACAM1-L was targeted to endothelia via the Tie2 promoter, and in Ceacam1-/- mice, the Ceacam1 gene was inactivated by targeted disruption (29). In addition, endothelial cells were transfected with cDNAs coding for WT CEACAM1-L and for CEACAM1-L mutants harboring amino acid substitutions in the cytoplasmic domain. In these experimental systems, we provide conclusive evidence that CEACAM1 is involved in angiogenesis ...
TY - JOUR. T1 - Clinical profile of a new monoclonal antibody-based immunoassay for tissue polypeptide antigen. AU - Correale, M.. AU - Arnberg, H.. AU - Blockx, P.. AU - Bombardier, E.. AU - Castelli, M.. AU - Encabo, G.. AU - Gion, M.. AU - Klapdor, R.. AU - Martin, M.. AU - Nilsson, S.. AU - Reutgen, H.. AU - Ruggeri, G.. AU - Safi, F.. AU - Stegmuller, M.. AU - Vering, A.. PY - 1994. Y1 - 1994. N2 - Our preliminary evaluation of a new monoclonal antibody-based assay for tissue polypeptide antigen (TPA) has shown it to be clinically equivalent to the polyclonal antibody-based assay for TPA. The new assay (TPA-M) employs three monoclonal antibodies to epitopes on cytokeratins 8, 18 and 19. This multicenter, multinational study included 266 patients with newly diagnosed carcinomas of the lung, breast, large bowel and urinary bladder. TPA values from the two assays were compared with three other cytokeratin markers (TPS, CYFRA 21-1 and TPA(Cyk)) and with the established reference markers for ...
There is a growing list of tumor-associated fetal substances that show diagnostic promise and may in time have immunotherapeutic and prophylactic value (1, 2). Malignancies of the digestive system have received special attention in this regard, especially since 1965, when Gold and Freedman (3) identified a tumor-specific glycoprotein antigen in human colonic carcinomas. This so-called carcinoembryonic antigen (CEA) is also present in other adenocarcinomas of entodermally derived digestive system epithelium, as well as in human fetal and embryonic gut, pancreas, and liver during the first two trimesters of pregnancy (4). The antigen is a predominantly carbohydrate material with a molecular ...
A long-range physical map of the carcinoembryonic antigen (CEA) gene family cluster, which is located on the long arm of chromosome 19, has been constructed. This was achieved by hybridization analysis of large DNA fragments separated by pulse-field gel electrophoresis and of DNA from human/rodent somatic cell hybrids, as well as the assembly of ordered sets of cosmids for this gene region into contigs. The different approaches yielded very similar results and indicate that the entire gene family is contained within a region located at position 19q13.1-q13.2 between the CYP2A and the D19S15/D19S8 markers. The physical linkage of nine genes belonging to the CEA subgroup and their location with respect to the pregnancy-specific glycoprotein (PSG) subgroup genes have been determined, and the latter are located closer to the telomere. From large groups of ordered cosmid clones, the identity of all known CEA subgroup genes has been confirmed either by hybridization using gene-specific probes or by ...
Definition of carcinoembryonic antigen. Provided by Stedmans medical dictionary and Drugs.com. Includes medical terms and definitions.
Materials. Peridinin chlorophyll protein-labeled anti-HLA-DR, FITC-conjugated anti-CD80, phycoerythrin (PE)-conjugated anti-CD86, PE-conjugated anti-CD40, and FITC-labeled anti-CD8 were purchased from BD Biosciences PharMingen (Chicago, IL). FITC-conjugated anti-HLA-A2 monoclonal antibody (clone BB7.2) was from Serotec Ltd. (Oxford, United Kingdom). Anti-human CEA (CE05) was from Neomarker (Fremont, CA). Anti-HSP27 (F-4), anti-HSP40 (C-20), anti-HSP60 (H-1), anti-HSP70 (K-20), anti-Hsc70 (B6), anti-intercellular adhesion molecule-1 (C-19), anti-B7.1 (N-20), anti-B7.2 (C-19), anti-transferrin receptor (K-20), and anti-lysosome-associated membrane glycoprotein-3 were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-MHC-I (HC10) was from Roswell Park Cancer Institute (Buffalo, NY). Horseradish peroxidase-coupled secondary antibodies were from Jackson ImmunoResearch (West Grove, PA). Recombinant mouse interleukin (IL)-2 and recombinant human IL-2 were commercially obtained from Sigma (St. ...
Receiver operating characteristic (ROC) curve was constructed to evaluate the diagnostic values. The results showed that AC096655.1-002 was significantly downregulated in gastric cancer tissues compared with paired adjacent non-tumorous tissues (P , 0.001). Its expression level was significantly correlated with lymph node metastasis (P , 0.001), distant metastasis (P , 0.001), tumor-node-metastasis stages (P , 0.001), and differentiation (P = 0.030). The area under the ROC curve of AC096655.1-002 was up to 0.731. For the detection of gastric cancer, the use of AC096655.1-002 showed a remarkable improvement compared with the use of serum carcinoembryonic antigen. These results indicated that lncRNA AC096655.1-002 may be a potential biomarker in the diagnosis of gastric carcinoma.. ...
Sensitive detection of cancer biomarkers is valuable for clinical diagnosis and treatment assessment of cancers. Herein, we report a simple smartphone-based double-channel fluorescent setup for immunoassay. Except the smartphone, the total cost of the detection device itself is about 80 $, including a laser
... A Dictionary to Tumor Markers and The Methods of Estimation Rahul R Nair, Jerin K Johnson protein(AFP), Carcinoembryonic antigen(CEA), Pancreatic oncofetal antigen) Abstract Tumor markers are substances produced by tumor cells or by other cells of the body in response to cancer or certain benign (noncancerous) conditions. These substances can be found in the blood, in the urine, in the tumor tissue, or in other tissues. Different tumor markers are found in different types of cancer, and levels of the same tumor marker can be altered in more than one type of cancer. In addition, tumor marker levels are not altered in all people with cancer, especially if the cancer is early stage. Some tumor marker levels can also be altered in patients with noncancerous conditions. To date, researchers have identified more than a dozen substances that seem to be expressed abnormally when some types of cancer are present. Some of these substances are also found in other conditions and diseases. Scientists ...
What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow-up? A systematic review and secondary analysis of a randomised controlled trial - Health Technology Assessment (free). Source: ACP Journal Wise ($). "The results suggest that (1) CEA testing should not be used alone as a triage test; (2) in year 1, testing frequency should be increased (to monthly for 3 months and then every 2 months); (3) the threshold for investigating a single test result should be raised to 10 µg/l; (4) after the second CEA test, decisions to investigate further should be made on the basis of the trend in CEA levels; (5) the optimal threshold for investigating the CEA trend falls over time; and (6) continuing smokers should not be monitored with CEA testing".. ...
The patients general condition must be studied and improved as much as possible, since the operation is one of the considerable magnitude. Unless there is evidence of acute or subacute obstruction, the patient is placed on a liquid diet for a day. Most patients receive a bowel preparation the afternoon or evening prior to surgery. Following complete evacuation of the colon with laxatives or purgative, appropriate nonabsorbable antibiotics may be given. Parenteral antibiotic coverage is given just prior to surgery. In the presence of low-lying tumors, it may be advisable to evaluate by cystoscopy whether or not the bladder or other portions of the genitourinary tract are involved. Basal carcinoembryonic antigen levels are determined before and after resection of the neoplasm. The extent of extramural spread or fixation to adjacent organs may be evaluated with endorectal ultrasound or MRI plus computed tomography (CT) imaging. ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from two Phase I studies evaluating the novel cancer immunotherapy CEA-TCB (RO6958688; RG7802), a molecule that binds T-cells and tumour cells simultaneously. CEA-TCB was studied in patients with carcinoembryonic antigen (CEA)-positive solid tumours, including microsatellite stable (MSS) metastatic colorectal cancers (mCRC) that overexpress CEA and progressed after at least two prior chemotherapy regimens.1 The studies demonstrated encouraging anti-tumour activity of CEA-TCB as a monotherapy, which was further enhanced in combination with TECENTRIQ® (atezolizumab). In the monotherapy, out of 31 patients with mCRC treated with CEA-TCB doses of 60mg or above, 14 patients (45%) showed either partial response (n=2, 6%) or stable disease (n=12, 39%). For the combination, of 25 patients treated with doses of 5-160mg of CEA-TCB, 11 patients with MSS mCRC were treated at doses shown to induce tumour lesion inflammation (80 and 160 mg). Nine of ...
Doctors give unbiased, helpful information on indications, contra-indications, benefits, and complications: Dr. Cohen on what is the cancer marker lab test cea something: The CEA (carcinoembryonic antigen) test is a colon cancer tumor marker. As with most tumor markers, it is not used as a screening test for colon cancer (in other words, it is not used to find the cancer because of a relatively high false positive rate) but it is used to monitor the cancer once it has been diagnosed. This is particularly useful for treated colon cancer to see if the tumor reoccurs.
CD4 (T4) is a single chain transmembrane glycoprotein and belongs to immunoglobulin supergene family. In extracellular region there are 4 immunoglobulin-like domains (1 Ig-like V-type and 3 Ig-like C2-type). Transmembrane region forms 25 aa, cytoplasmic tail consists of 38 aa. Domains 1,2 and 4 are stabilized by disulfide bonds. The intracellular domain of CD4 is associated with p56Lck, a Src-like protein tyrosine kinase. It was described that CD4 segregates into specific detergent-resistant T-cell membrane microdomains ...
Considerations for a carcinoembryonic antigen test include smoking, cirrhosis and other factors that can raise CEA levels in the blood of those who do not have cancer, explains Drexel University...
Among patients who had undergone curative surgery for primary colorectal cancer, the screening methods of computed tomography and carcinoembryonic antigen each provided an improved rate of surgical treatment of cancer recurrence ...
Our literature search identified 93 studies evaluating an overall of 70 different blood markers for CRC, including long discussed ones like carcinoembryonic antigen and carbohydrate antigens, as well as newly introduced ones like proteins identified through MS analysis. A broad timeframe with first studies from 1979 (75) to 2006 (49, 73, 74, 77, 81, 89-91, 102) was covered. The majority of studies evaluated protein markers, but in recent years, an interesting number of studies also evaluated genetic and epigenetic markers.. Overall, a broad range of sensitivity and specificity was reported for the various markers. A direct comparison of results from different studies is complicated due to the diverse populations used (different age, origin, "normal," or diseased controls), the diverse number of markers evaluated (single versus combined markers) and use of different cutoff points for the same marker (M2-PK and CEA). Furthermore, the majority of markers were evaluated in only one study, especially ...
CEA (carcinoembryonic antigen) has an identity with an antigen of the mucous colic embryo, from which it takes its name, and is associated with colorectal
Thompson, John A.; Mössinger, S.; Reichhardt, V.; Engels, U.; Beauchemin, N.; Komoss, F.; Kleist, Sabine von und Zimmermann, Wolfgang (9. September 1993): A Polymerase-chain-reaction Assay for the Specific Identification of Transcripts Encoded by Individual Carcinoembryonic Antigen (CEA)-gene-family Members. In: International Journal of Cancer, Vol. 55, Nr. 2: S. 311-319 [PDF, 1MB] ...
Antibodies, Antigen, Carcinoembryonic Antigen, Chorionic Gonadotropin, Gonadotropin, Hormone, Human, Human Chorionic Gonadotropin, Immobilization, Immobilized Proteins, Immunoglobulin, Immunoglobulin G, Ionic Strength, Isoelectric Points, Magnetic, Microbeads, Nanoparticles, Orientation, Peroxidase, PH
Current disease and contamination sensors require expensive readout equipment or trained personnel. Yuehe Lin, Yong Tang and colleagues propose a new detection system based on pressure changes. For example, when a disease biomarker is present, it causes a chain reaction in the device that results in oxygen being released and pressure building. The pressure changes are measured by a portable barometer, and smartphone software provides an easy readout of the results.. To show the versatility of the pressure sensor, the team tested a variety of applications. Prototypes could detect carcinoembryonic antigen, a protein present in high levels in patients with colon or rectal cancer; ractopamine, which is an animal-feed additive banned in many countries; and thrombin, a cardiovascular disease marker. In addition, a mercury-ion sensor was developed for environmental pollution monitoring. The researchers say that because the results are immediately available with a smartphone, the method could enable ...
One hundred ninety-one unselected fluid specimens submitted routinely for cytologic examination were assayed to determine whether the measurement of carcinoembryonic antigen (CEA) levels in pleural effusions is useful in detecting malignancy. The mean ± SD CEA level of 103 benign effusions was 4.1 ± 2.9 ng/ml. Only one benign effusion had a level , 12 ng/ml (18 ng/ml). Benign inflammatory effusions (pneumonia, empyema) had a higher mean CEA activity (6.2 ± 3.4) than effusions caused by congestive heart failure (2.9 ± 1.5) (p , 0.001). Twenty-four (34%) of 70 malignant effusions had a CEA level greater than 12 ng/ml, and 28 (40%) were "positive" by cytologic study. Thirty-eight (54%) were detected by one or both methods. Ten malignant effusions were positive by CEA (, 12 ng/ml) alone. These data suggest that the determination of CEA activity levels, when used in conjunction with other clinical findings, may be useful in detecting malignant pleural effusions. ...
Serum half-life of IgG is controlled by the neonatal Fc receptor (FcRn) that interacts with the IgG Fc region and may be increased or decreased as a function of altered FcRn binding. Preclinical evaluations of modified IgGs are frequently carried out in mice, but such IgGs may bind differently to mouse and human FcRn (mFcRn and hFcRn). Here, we report a detailed characterization of a matched set of mouse-human chimeric T84.66 scFv-Fc variants with specificity for the tumor carcinoembryonic antigen and mutations in the FcRn-binding site. Binding to soluble mFcRn and hFcRn was measured using in vitro assays, and the results were compared with blood clearance in vivo in normal (mFcRn bearing) and hFcRn transgenic mice. All variants bound better to mFcRn than to hFcRn. The loss of affinity varied among the mutants, however, and also the hierarchy of binding differed depending on the receptor. The mutations had no major impact on binding to the classical Fcγ receptors. Importantly, the trend of blood
Dr. Blumberg is Professor of Medicine, Harvard Medical School, Chief of Gastroenterology, Brigham and Womens Hospital, co-Director of the Harvard Digestive Diseases Center and past-Director of the Brigham Research Institute. He has directed a National Institutes of Health funded laboratory since 1989 which has a particular emphasis on the immunologic functions of the intestinal epithelium; a field that his laboratory has pioneered through the study of non classical MHC class I molecules and more recently the unfolded protein response and Paneth cell function and is a leading authority on carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) and the neonatal crystallizable fragment receptor (FcRn) function. Dr. Blumberg has been the recipient of the an NIH Method to Extend Research in Time (M.E.R.I.T) Award (2005), the William Beaumont Prize (2009), the CCFA Scientific Achievement Award in Inflammatory Bowel Disease Basic Research (2012), a Lifetime Scientific Achievement Award from the ...
Medullary thyroid carcinoma (MTC) is a differentiated neuroendocrine tumor, mostly slowly growing with a relative good prognosis, with an overall 10-year survival of 61-76% [1,2]. Surgery is the only curative therapy for MTC [3]. After surgery, patients with MTC should be assessed regarding the presence of residual disease, the localization of metastases and the identification of progressive disease. Postoperative staging is used to separate low-risk from high-risk patients with MTC [4]. The TNM system utilizes tumor size, extrathyroidal invasion, nodal metastasis and distant spread of cancer. The number of lymph node metastases and involved compartments as well as postoperative serum calcitonin (CTN) and carcinoembryonic antigen (CEA) levels should be documented in addition. The normalization of serum CTN levels postoperatively is associated with an excellent prognosis (10-year survival ,95%).. Click here to view the full article in our partner journal the International Journal of Endocrine ...
Squamous cell carcinoma antigen: a role in the early identification of nodal metastases in men with squamous cell carcinoma of the penis. To evaluate whether serum squamous cell carcinoma antigen (SCCAg) measurements may be of use in identifying nodal metastases in patients with SCC of the penis after treating the primary tumour. The levels of SCCAg were analysed in 11 men with penile SCC between 1994 and 2001. An elevated SCCAg level had a sensitivity of 57% (95% confidence interval, CI, 18-90%) and a specificity of 100% (CI 40-100%) for nodal metastases. Levels of SCCAg increased exponentially in patients who developed nodal metastases after treatment of the primary tumour, and were elevated before clinical or radiological evidence of nodal disease. Either the absolute level or the rate of rise of SCCAg may be a useful tool with which to follow patients after excision of the primary tumour. It may be more sensitive than computed tomography and magnetic resonanc imaging in detecting recurrence, ...
This study compared the sensitivity and specificity of CA 50 and CA 19-9 as serum tumour markers for pancreatic cancer. One hundred and seventy one subjects were evaluated: 50 healthy controls, 50 patients with pancreatic carcinoma and 71 patients with chronic pancreatitis. Eighty per cent of the pancreatic cancer patients had raised CA 19-9 serum levels and 82% had raised CA 50 serum levels. In the group of patients ith chronic pancreatitis, false positive tests occurred in 8.4% for CA 19-9 and 11.3% for CA 50. For both markers the serum level showed a severe elevation in the advanced stage of cancer disease. Despite the good sensitivity and specificity of CA 50 as a serum tumour marker for pancreatic carcinoma, no major advantage was found compared to CA 19-9. Moreover, if the CA 50 cut-off, level is raised to 85 U/ml to exclude overlap with chronic pancreatitis, sensitivity falls sharply to 46% compared with 72% for CA 19-9 when a 100 U/ml cut-off level is used.. ...
Background Linifanib is a potent and selective VEGF and PDGF receptor inhibitor that has activity in unselected, advanced NSCLC patients (pts) both as monotherapy in the relapsed setting and with carboplatin (C) and paclitaxel (P) in the first-line setting. A baseline plasma biomarker signature identifying NSCLC pts most sensitive to linifanib is needed.. Methods An exploratory retrospective analysis of 4 randomized clinical trials (linifanib or other treatments: ABT-510 [thrombospondin mimetic], pemetrexed +/- ABT-751 [tubulin inhibitor], docetaxel +/- ABT-751) in relapsed NSCLC was conducted. Evaluable baseline plasma samples were obtained from 116 pts who received linifanib and 125 pts on other treatments. A signature combining established tumor markers (carcinoembryonic antigen [CEA] and fragments of cytokeratin 19 [CYFRA 21-1]) was derived using a sequential BATTing approach. The signature was then tested across a randomized trial of CP + placebo, linifanib 7.5 mg, or linifanib 12.5 mg in ...
Pneumonic plague, caused by inhalation of Yersinia pestis, represents a major bioterrorism threat for which no vaccine is available. Based on the knowledge that genetic delivery of monoclonal antibodies (MAbs) with adenovirus (Ad) gene transfer vectors results in rapid, high-level antibody expression, we evaluated the hypothesis that Ad-mediated delivery of a neutralizing antibody directed against the Y. pestis V antigen would protect mice against a Y. pestis challenge. MAbs specific for the Y. pestis V antigen were generated, and the most effective in protecting mice against a lethal intranasal Y. pestis challenge was chosen for further study. The coding sequences for the heavy and light chains were isolated from the corresponding hybridoma and inserted into a replication-defective serotype 5 human Ad gene transfer vector (AdαV). Western analysis of AdαV-infected cell supernatants demonstrated completely assembled antibodies reactive with V antigen. Following AdαV administration to mice, ...

Ceacam12 (untagged) - Mouse carcinoembryonic antigen-related cell adhesion molecule 12 (Ceacam12), transcript variant 1, (10ug)...Ceacam12 (untagged) - Mouse carcinoembryonic antigen-related cell adhesion molecule 12 (Ceacam12), transcript variant 1, (10ug)...

Mouse carcinoembryonic antigen-related cell adhesion molecule 12 (Ceacam12), transcript variant 1, (10ug), 10 µg. ... Home » cDNA » Mouse cDNA » Ceacam12 (untagged) - Mouse carcinoembryonic antigen-related cell adhesion molecule 12 (Ceacam12), ... MC210519 Ceacam12 (untagged) - Mouse carcinoembryonic antigen-related cell adhesion molecule 12 (Ceacam12), transcript variant ... Properties for Ceacam12 (untagged) - Mouse carcinoembryonic antigen-related cell adhesion molecule 12 (Ceacam12), transcript ...
more infohttps://www.acris-antibodies.com/cdna/mouse-cdna/ceacam12-untagged-mouse-carcinoembryonic-antigen-related-cell-adhesion-molecule-12-ceacam12-transcript-variant-1-10ug-mc210519.htm

Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or...Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or...

Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H1 2016 report by Global ... Global Markets Directs, Carcinoembryonic Antigen-Related Cell Adhesion Molecule... ... 54 Pages Report] Check for Discount on Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 ( ... Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or ...
more infohttp://www.reportsnreports.com/reports/640458-carcinoembryonic-antigen-related-cell-adhesion-molecule-5-carcinoembryonic-antigen-or-cea-or-meconium-antigen-100-or-cd66e-or-ceacam5-pipeline-review-h1-2016.html

CEACAM18 elisa kit | Canine Carcinoembryonic antigen-related cell adhesion molecule 18 (CEACAM18) ELISA Kit-NP 082512.1CEACAM18 elisa kit | Canine Carcinoembryonic antigen-related cell adhesion molecule 18 (CEACAM18) ELISA Kit-NP 082512.1

Canine Carcinoembryonic antigen-related cell adhesion molecule 18 (CEACAM18) ELISA Kit-NP_082512.1 (MBS7211769) product ... Carcinoembryonic antigen-related cell adhesion molecule 18 (CEACAM18), ELISA Kit. Also Known As Canine Carcinoembryonic antigen ... carcinoembryonic antigen-related cell adhesion molecule 18 NCBI Official Synonym Full Names carcinoembryonic antigen-related ... Carcinoembryonic antigen-related cell adhesion molecule 18 Protein Family Carcinoembryonic antigen-related cell adhesion ...
more infohttps://www.mybiosource.com/prods/ELISA-Kit/Canine/Carcinoembryonic-antigen-related-cell-adhesion-molecule-18-CEACAM18/CEACAM18/datasheet.php?products_id=7211769

Durchsuchen nach  PersonenDurchsuchen nach Personen

Long-Range Chromosomal Mapping of the Carcinoembryonic Antigen (CEA) Gene Family Cluster. In: Genomics, Vol. 12, Nr. 4: S. 761- ...
more infohttps://epub.ub.uni-muenchen.de/view/autoren/Schleussner=3ACathrin=3A=3A.html

北京大学医学部机构知识库(IR@PKUHSC): Clinical application of radioimmunoguided surgery in colorectal cancer using I-125-labeled...北京大学医学部机构知识库([email protected]): Clinical application of radioimmunoguided surgery in colorectal cancer using I-125-labeled...

PURPOSE: The aim of this study was to evaluate the applicability of I-125-labeled carcinoembryonic antigen-specific monoclonal ... Clinical application of radioimmunoguided surgery in colorectal cancer using I-125-labeled carcinoembryonic antigen-specific ... Clinical application of radioimmunoguided surgery in colorectal cancer using I-125-labeled carcinoembryonic antigen-specific ... Clinical application of radioimmunoguided surgery in colorectal cancer using I-125-labeled carcinoembryonic antigen-specific ...
more infohttp://ir.bjmu.edu.cn/handle/400002259/65042

PSG3 antibodies | AntibodypediaPSG3 antibodies | Antibodypedia

Molecular cloning and analysis of several PSG genes has indicated that the PSGs form a subgroup of the carcinoembryonic antigen ...
more infohttps://www.antibodypedia.com/gene/21555/PSG3

Carcinoembryonic antigen - WikipediaCarcinoembryonic antigen - Wikipedia

In humans, the carcinoembryonic antigen family consists of 29 genes, 18 of which are normally expressed. The following is a ... Carcinoembryonic Antigen at the US National Library of Medicine Medical Subject Headings (MeSH) CEA at Lab Tests Online CEA: ... Carcinoembryonic antigen (CEA) describes a set of highly related glycoproteins involved in cell adhesion. CEA is normally ... Ballesta, AM; Molina, R; Filella, X; Jo, J; Giménez, N (1995). "Carcinoembryonic antigen in staging and follow-up of patients ...
more infohttps://en.wikipedia.org/wiki/Carcinoembryonic_antigen

Carcinoembryonic AntigenCarcinoembryonic Antigen

... is an antigen (protein) present in very small quantities in adult tissue. A greater than normal amount may be suggestive of ... Carcinoembryonic antigen (CEA) is an antigen (protein) present in very small quantities in adult tissue. A greater than normal ... It is also referred to as an oncofetal antigen because of its similarity to fetal tissue. ... www.healthcentral.com/encyclopedia/carcinoembryonic-antigen. Encyclopedia /C /. Carcinoembryonic Antigen. Carcinoembryonic ...
more infohttps://www.healthcentral.com/encyclopedia/carcinoembryonic-antigen

Carcinoembryonic Antigen | HealthCentralCarcinoembryonic Antigen | HealthCentral

... is an antigen (protein) present in very small quantities in adult tissue. A greater than normal amount may be suggestive of ... Carcinoembryonic antigen (CEA) is an antigen (protein) present in very small quantities in adult tissue. A greater than normal ... It is also referred to as an oncofetal antigen because of its similarity to fetal tissue. ... www.healthcentral.com/encyclopedia/carcinoembryonic-antigen. Encyclopedia /C /. Carcinoembryonic Antigen. Carcinoembryonic ...
more infohttps://healthcentral.com/encyclopedia/carcinoembryonic-antigen

Carcinoembryonic antigen definition | Drugs.comCarcinoembryonic antigen definition | Drugs.com

Definition of carcinoembryonic antigen. Provided by Stedmans medical dictionary and Drugs.com. Includes medical terms and ... carcinoembryonic antigen. Definition: a glycoprotein constituent of the glycocalyx of embryonic endodermal epithelium, which ...
more infohttps://www.drugs.com/dict/carcinoembryonic-antigen.html

Carcinoembryonic antigen (CEA) - Canadian Cancer SocietyCarcinoembryonic antigen (CEA) - Canadian Cancer Society

Carcinoembryonic antigen (CEA) is a protein normally found in the tissue of a developing fetus. Levels of CEA in the blood ... Carcinoembryonic antigen (CEA). Carcinoembryonic antigen (CEA) is a protein normally found in very low levels in the blood of ... Cancer information / Diagnosis and treatment / Tests and procedures / Carcinoembryonic antigen (CEA) Select the text below and ...
more infohttp://www.cancer.ca/en/cancer-information/diagnosis-and-treatment/tests-and-procedures/carcinoembryonic-antigen-cea/?region=qc

France - CARCINOEMBRYONIC ANTIGEN. - Free Online LibraryFrance - CARCINOEMBRYONIC ANTIGEN. - Free Online Library

CARCINOEMBRYONIC ANTIGEN. by Mena Report; Business, international Carcinoembryonic antigen CEA (Oncology) ... ANTIGEN.-a0313924654,/a,. Citations: *MLA style: "France - CARCINOEMBRYONIC ANTIGEN.." The Free Library. 2013 Al Bawaba (Middle ... ANTIGEN.-a0313924654. *Chicago style: The Free Library. S.v. France - CARCINOEMBRYONIC ANTIGEN.." Retrieved Dec 10 2017 from ... ANTIGEN.-a0313924654. *APA style: France - CARCINOEMBRYONIC ANTIGEN.. (n.d.) >The Free Library. (2014). Retrieved Dec 10 2017 ...
more infohttps://www.thefreelibrary.com/France+-+CARCINOEMBRYONIC+ANTIGEN-a0313924654

Synthesis of Carcinoembryonic Antigen in vitro | Nature New BiologySynthesis of Carcinoembryonic Antigen in vitro | Nature New Biology

... carcinoembryonic antigen (CEA), provides a suitable candidate for studying one such property related to a particular type of ... It has been proposed, however, that tumour-specific antigens such as CEA are not indigenous to the tumours, but are ... It therefore seems reasonable to expect that cell products such as tumour-associated antigens could, if present from the outset ... In vitro carcinoembryonic antigen production by human gastric carcinoma xenograft in nude mice *Ivy Benjamin ...
more infohttps://www.nature.com/articles/newbio239189a0?error=cookies_not_supported&code=0728945d-8541-4dcc-aae7-ec7625afb79d

Carcinoembryonic antigen peptide-1 - WikipediaCarcinoembryonic antigen peptide-1 - Wikipedia

Carcinoembryonic antigen peptide-1 is a nine amino acid peptide fragment of carcinoembryonic antigen (CEA), a protein that is ... Synonyms: CAP-1 Carcinoembryonic Antigen Peptide-1 Carcinoembryonic Peptide-1 CEA Peptide 1 CEA Peptide 9-mer National Cancer ...
more infohttps://en.wikipedia.org/wiki/Carcinoembryonic_antigen_peptide-1

Carcinoembryonic AntigenCarcinoembryonic Antigen

This test measures a protein called carcinoembryonic antigen (CEA) in your blood. This protein is present on some types of ... Carcinoembryonic Antigen. Does this test have other names?. CEA. What is this test?. This test measures a protein called ... carcinoembryonic antigen (CEA) in your blood. This protein is found on some types of cancer cells. ...
more infohttp://healthlibrary.brighamandwomens.org/Conditions/Diabetes/167,carcinoembryonic_antigen

Prospective study of the quantitative carcinoembryonic antigen an...: Ingenta ConnectProspective study of the quantitative carcinoembryonic antigen an...: Ingenta Connect

In this prospective study, we examined the usefulness of the carcinoembryonic antigen (CEA) and cytokeratin 20 (CK20) mRNA ... Prospective study of the quantitative carcinoembryonic antigen and cytokeratin 20 mRNA detection in peritoneal washes to ...
more infohttps://www.ingentaconnect.com/content/sp/or/2007/00000017/00000003/art00025

CEA (Carcinoembryonic Antigen) TestCEA (Carcinoembryonic Antigen) Test

The carcinoembryonic antigen (CEA) test is used to screen for cancer. Request A Test offers 100s of locations nationwide for ... CEA (Carcinoembryonic Antigen) Blood Test. This test measures the level of Carcinoembryonic Antigen (CEA) in the blood. CEA is ... CEA (Carcinoembryonic Antigen) Blood Test. This test measures the level of Carcinoembryonic Antigen (CEA) in the blood. CEA is ... CEA (Carcinoembryonic Antigen) Blood Test. This test measures the level of Carcinoembryonic Antigen (CEA) in the blood. CEA is ...
more infohttps://requestatest.com/carcinoembryonic-antigen-cea-testing

Carcinoembryonic Antigen | Annals of Internal Medicine | American College of PhysiciansCarcinoembryonic Antigen | Annals of Internal Medicine | American College of Physicians

Carcinoembryonic Antigen Levels in Benign and Malignant Pleural Effusions Annals of Internal Medicine; 88 (5): 631-634 ... The level of carcinoembryonic antigen (CEA) is often elevated in the serum of patients with cancer. This article reviews the ... Sequential Carcinoembryonic Antigen Levels in the Therapy of Metastatic Breast Cancer: A Predictor and Monitor of Response and ... Carcinoembryonic Antigen Elevation in Renal Failure Annals of Internal Medicine; 91 (6): 867-868 ...
more infohttp://annals.org/aim/article-abstract/1077420/carcinoembryonic-antigen

Carcinoembryonic Antigen - AHealthyMe - Blue Cross Blue Shield of MassachusettsCarcinoembryonic Antigen - AHealthyMe - Blue Cross Blue Shield of Massachusetts

This test measures a protein called carcinoembryonic antigen (CEA) in your blood. This protein is present on some types of ... Carcinoembryonic Antigen. Does this test have other names?. CEA. What is this test?. This test measures a protein called ... carcinoembryonic antigen (CEA) in your blood. This protein is found on some types of cancer cells. ...
more infohttp://www.ahealthyme.com/Library/DiseasesConditions/Adult/Diabetes/167,carcinoembryonic_antigen

Carcinoembryonic Antigen - AHealthyMe - Blue Cross Blue Shield of MassachusettsCarcinoembryonic Antigen - AHealthyMe - Blue Cross Blue Shield of Massachusetts

This test measures a protein called carcinoembryonic antigen (CEA) in your blood. This protein is present on some types of ... Carcinoembryonic Antigen. Does this test have other names?. CEA. What is this test?. This test measures a protein called ... carcinoembryonic antigen (CEA) in your blood. This protein is found on some types of cancer cells. ...
more infohttp://www.ahealthyme.com/Library/DiseasesConditions/Pediatric/Oncology/167,carcinoembryonic_antigen

Carcinoembryonic Antigen (CEA) Detection: Antibodies and ProteinsCarcinoembryonic Antigen (CEA) Detection: Antibodies and Proteins

Alternate names for CEA include carcinoembryonic antigen-related cell adhesion molecule, CD66, meconium antigen, biliary ... Carcinoembryonic antigen (CEA) is a glycosylphosphatidylinositol (GPI)-cell surface anchored glycoprotein, first identified in ... Antigen/protein. Cat. #. Application. Species. (Clone) and Source. Cross‑Reactivity. CEA. 10094A, B, C. IHC. Human. (1B2). ... Does not cross‑react with CEA antisera such as nonspecific cross-reacting antigen (NCA) derived from lung and spleen, NCA-2 ...
more infohttp://www.clontech.com/US/Products/Cell_Biology_and_Epigenetics/Cancer_and_Inflammation/CEA?sitex=10020:22372:US&PEBCL1=U7vaohiH8ifjQvlKsgsfJvBxoF&PEBCL1_pses=ZG3D6AF74E9D98899D4B130EA2AFBCDF10106DB50E762AB687E016D48E815425819249150372F91326220512F0BB1E0C671CB74E28AE777A6B

Carcinoembryonic Antigen (CEA) Detection: Antibodies and ProteinsCarcinoembryonic Antigen (CEA) Detection: Antibodies and Proteins

Alternate names for CEA include carcinoembryonic antigen-related cell adhesion molecule, CD66, meconium antigen, biliary ... Carcinoembryonic antigen (CEA) is a glycosylphosphatidylinositol (GPI)-cell surface anchored glycoprotein, first identified in ... Antigen/protein. Cat. #. Application. Species. (Clone) and Source. Cross‑Reactivity. CEA. 10094A, B, C. IHC. Human. (1B2). ... Does not cross‑react with CEA antisera such as nonspecific cross-reacting antigen (NCA) derived from lung and spleen, NCA-2 ...
more infohttp://www.clontech.com/US/Products/Cell_Biology_and_Epigenetics/Cancer_and_Inflammation/CEA?sitex=10020:22372:US&PEBCL1=qSbroK0XVl2M3qmaoon3MBEEpB&PEBCL1_pses=ZG3ABEB470B5C8FB5C15C3F1B67A74C638C80908BEEC101A9D1D638718B1FB38AF74212242DB400D807EADFE5FE8F89A2EFF9F942CFEE1E4D0

Carcinoembryonic Antigen | Harvard Catalyst Profiles | Harvard CatalystCarcinoembryonic Antigen | Harvard Catalyst Profiles | Harvard Catalyst

"Carcinoembryonic Antigen" by people in Harvard Catalyst Profiles by year, and whether "Carcinoembryonic Antigen" was a major or ... "Carcinoembryonic Antigen" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical ... Below are the most recent publications written about "Carcinoembryonic Antigen" by people in Profiles. ... Below are MeSH descriptors whose meaning is more general than "Carcinoembryonic Antigen". ...
more infohttps://connects.catalyst.harvard.edu/Profiles/display/Concept/Carcinoembryonic%20Antigen

Carcinoembryonic antigen-related cell adhesion molecule 1 - DrugBankCarcinoembryonic antigen-related cell adhesion molecule 1 - DrugBank

Carcinoembryonic antigen-related cell adhesion molecule 1. Details. Name. Carcinoembryonic antigen-related cell adhesion ... Carcinoembryonic antigen-related cell adhesion molecule 1. P13688. Details. Drug Relations. Drug Relations. DrugBank ID. Name. ...
more infohttps://www.drugbank.ca/bio_entities/BE0000107

Carcinoembryonic Antigen, FluidCarcinoembryonic Antigen, Fluid

Carcinoembryonic Antigen Fluid Source. PROMPT. N. 31208-2. 0020743. Carcinoembryonic Antigen, Fluid. Resultable. N. ng/mL. ... Carcinoembryonic Antigen Fluid Source. 31208-2. * Component test codes cannot be used to order tests. The information provided ...
more infohttp://ltd.aruplab.com/Tests/Pub/0020742
  • The ELISA analytical biochemical technique of the MBS7211769 kit is based on CEACAM18 antibody-CEACAM18 antigen interactions (immunosorbency) and an HRP colorimetric detection system to detect CEACAM18 antigen targets in samples. (mybiosource.com)
  • MBS7211769 is a ready-to-use microwell, strip plate ELISA (enzyme-linked immunosorbent assay) Kit for analyzing the presence of the Carcinoembryonic antigen-related cell adhesion molecule 18 (CEACAM18) ELISA Kit target analytes in biological samples. (mybiosource.com)
  • In eccrine sweat, carcinoembryonic antigen activities were at least thirty times that in serum, using a radioimmunoassay. (em-consulte.com)
  • Carcinoembryonic antigen, as measured by radioimmunoassay, is present in two different human colonic tumors that have been serially transplanted and maintained in the cheek pouches of unconditioned, adult golden hamsters. (sciencemag.org)
  • In this prospective study, we examined the usefulness of the carcinoembryonic antigen (CEA) and cytokeratin 20 (CK20) mRNA detection in peritoneal washes as a prophylactic tool for peritoneal recurrence. (ingentaconnect.com)
  • Our studies have confirmed that raised plasma levels of carcinoembryonic antigen (C.E.A.) occur with many but not all malignant tumours, particularly those of the gastrointestinal tract, breast, and bronchus. (bmj.com)
  • Carcinoembryonic antigen is also present in the cuticle which lines the duct. (em-consulte.com)
  • It has been proposed, however, that tumour-specific antigens such as CEA are not indigenous to the tumours, but are glycoproteins produced elsewhere in the body and coating the tumour cells secondarily 3 . (nature.com)
  • Carcinoembryonic Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (harvard.edu)
  • The carcinoembryonic antigen (CEA) test is used to monitor a person before and during treatment. (kaiserpermanente.org)
  • Carcinoembryonic antigen may form part of the Schiff-positive cuticle and function in the normal homeostasis of eccrine and apocrine glands. (em-consulte.com)
  • This graph shows the total number of publications written about "Carcinoembryonic Antigen" by people in Harvard Catalyst Profiles by year, and whether "Carcinoembryonic Antigen" was a major or minor topic of these publication. (harvard.edu)